<SEC-DOCUMENT>0001140361-21-038586.txt : 20211118
<SEC-HEADER>0001140361-21-038586.hdr.sgml : 20211118
<ACCEPTANCE-DATETIME>20211118171155
ACCESSION NUMBER:		0001140361-21-038586
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20211118
DATE AS OF CHANGE:		20211118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-261185
		FILM NUMBER:		211425323

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>ny20001244x1_s1.htm
<DESCRIPTION>S-1
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 7.7.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="ny20001244x1_s1_100-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 25pt; text-align: center;">As filed with the Securities and Exchange Commission on November 18, 2021.</div><div class="regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 1pt; text-align: right;">Registration No. 333-&#8195;&#8195;&#8195; </div></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">WASHINGTON, D.C. 20549</font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 18pt;">FORM S-1</font><br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 24pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">BROOKLYN IMMUNOTHERAPEUTICS, INC.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 24pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt; font-style: italic; font-weight: normal;">(Exact name of registrant as specified in its charter)</font></div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 31.85%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2836</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">31-1103425</div></td></tr><tr><td style="width: 31.85%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">(State or other jurisdiction of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">incorporation or organization)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">(Primary Standard Industrial <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">Classification Code Number)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">(I.R.S. Employer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">Identification Number)</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">140 58th Street, Suite 2100<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Brooklyn, New York 11220<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: italic; font-weight: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">Howard J. Federoff<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Chief Executive Officer and President<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Brooklyn ImmunoTherapeutics, Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">140 58<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Street, Suite 2100<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Brooklyn, New York 11220<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Telephone: (212) 582-1199<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-style: italic; font-weight: normal;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.5pt; text-align: center;">Copies to:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">Mark L. Johnson<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Bella Zaslavsky <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">K&amp;L Gates LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">One Lincoln Street<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Boston, Massachusetts 02111<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Telephone: (617) 261-3100</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">Approximate date of commencement of proposed sale to the public:<font style="font-weight: normal;"> As soon as practicable after this Registration Statement is declared effective.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 1pt; margin-left: 0pt; text-align: justify;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. &#x2612; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 1pt; margin-left: 0pt; text-align: justify;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#8201;&#x2610; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 1pt; margin-left: 0pt; text-align: justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#8201;&#x2610; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 1pt; margin-left: 0pt; text-align: justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#8201;&#x2610; </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 1pt; margin-left: 0pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 44.44%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 8pt;">&#x2610;</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 44.44%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 8pt;">&#x2610;</font></div></td></tr><tr><td style="width: 44.44%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-accelerated filer</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 44.44%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612;</div></td></tr><tr><td style="width: 44.44%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 44.44%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 2.22%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 8pt;">&#x2610;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 1pt; margin-left: 0pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided in Section 7(a)(2)(B) of the Securities Act. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; text-align: center;">CALCULATION OF REGISTRATION FEE</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 2pt;"> </div></div><table cellspacing="0" cellpadding="0" class="regtab" style="margin-top: 4pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto; border-top: 1pt solid #000000; border-bottom: 1pt solid #000000;"><tr class="header"><td style="width: 35.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title of Each Class of Securities to be Registered</div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount to be <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Registered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed Maximum <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offering Price Per <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed Maximum <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate Offering <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 4.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount of <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Registration Fee<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td></tr><tr><td style="width: 35.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common stock, par value $0.005 per share<font style="padding-left: 2.9pt;"></font></div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.5pt; text-align: left;">6,281,454</div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.25pt; text-align: left;">$7.80</div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$48,995,341.20</div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.5pt; text-align: left;">$4,541.87</div></td></tr></table><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The shares will be offered for resale by the selling stockholders. Pursuant to Rule 416 under the Securities Act of 1933, this registration statement also covers any additional number of shares of common stock issuable upon stock splits, stock dividends, dividends or other distribution, recapitalization or similar events with respect to the shares of common stock being registered pursuant to this registration statement.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 1pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, based on the average of the high and low prices per share of common stock as reported on The Nasdaq Global Market on November&#160;16, 2021.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 1pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Pursuant to Rule 457(p) under the Securities Act of 1933, the filing fee for this registration statement has been offset in full by fees totaling $8,011.23 paid in connection with the Registration Statement on Form S-3 (File No: 333-258816) filed by the Registrant. Such registration statement was withdrawn pursuant to a Form RW filed on November 18, 2021. Such registration statement was not declared effective and no securities were sold thereunder.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a), may determine.</div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20001244x1_s1_101-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><div style="font-family: Arial, Helvetica, sans-serif; text-align: left; margin-bottom: 12pt;">The information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and the selling stockholders named in this prospectus are not soliciting offers to buy these securities, in any jurisdiction where the offer or sale is not permitted.</div>Subject to completion, dated November 18, 2021</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">PROSPECTUS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 108px; width: 425px;" src="logo_brooklyn.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 12.5pt; text-align: center;">6,281,454 Shares</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 12pt; text-align: center;">Common Stock </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-align: justify;">This prospectus relates to resales of shares of common stock, par value $0.005 per share, previously issued by us to the selling stockholders, as identified on page <a href="#tPSS">12</a> of this prospectus, in connection with our acquisition of Novellus, Inc., a Delaware corporation that is the sole equity holder of Novellus Therapeutics Limited. We will not receive any proceeds from the sale of the shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-align: justify;">The selling stockholders, or their pledgees, donees, transferees or other successors-in-interest, may offer the shares from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. We will not receive any of the proceeds from the sale of shares of common stock by the selling stockholders. We will bear all costs, expenses and fees in connection with the registration of the common stock. The selling stockholders will bear all commissions and discounts and transfer taxes, if any, attributable to their sale of common stock. For more information, see &#8220;Plan of Distribution&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-align: justify;">The common stock is listed on The Nasdaq Global Market under the symbol &#8220;BTX.&#8221; On November 16, 2021, the closing sale price of the common stock as reported on The Nasdaq Global Market was $7.72. You are urged to obtain current market quotations for the common stock. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: justify;">Our business and an investment in the common stock involve significant risks. See &#8220;Risk Factors&#8221; included on page <a href="#tRF">4</a> of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: justify;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-align: justify;">The selling stockholders may sell the shares of common stock offered by this prospectus in a number of different ways and at varying prices, as described in &#8220;Plan of Distribution&#8221; on page <a href="#tPD">17</a>.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-align: justify;">We have agreed to bear all of the expenses incurred in connection with the registration of the shares of common stock offered by this prospectus. The selling stockholders will pay or assume any discounts, commissions, or fees of underwriters, selling brokers or dealer managers incurred in connection with its sales of the shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-align: justify;">As a &#8220;smaller reporting company&#8221; under applicable rules of the Securities and Exchange Commission, we have elected to comply with certain reduced public company disclosure requirements for this prospectus and other filings with the Securities and Exchange Commission. See &#8220;Prospectus Summary&#8212;Implications of Being a Smaller Reporting Company.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 62pt; text-align: center;">The date of this prospectus is &#8195;&#8195;&#8195;&#8195;, 2021.</div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_102-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.54%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PAGE</div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP">ABOUT THIS PROSPECTUS<font style="padding-left: 4.33pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tATP"><font style="padding-left: 4.44pt;">ii</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS">PROSPECTUS SUMMARY<font style="padding-left: 2.84pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tPS"><font style="padding-left: 5pt;">1</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">4</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.2pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tFLS"><font style="padding-left: 5pt;">9</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tUP"><font style="padding-left: 0.37pt;">11</font></a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSS">PRINCIPAL AND SELLING STOCKHOLDERS<font style="padding-left: 2.68pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tPSS">12</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDCS">DESCRIPTION OF CAPITAL STOCK<font style="padding-left: 3.11pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tDCS">14</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tPD">17</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tLM">19</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tEXP">19</a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYCFMI">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 3.84pt;"></font></a></div></td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.54%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.81pt; text-align: left;"><a href="#tWYCFMI">19</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_103-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission. Before making your investment decision, we urge you to carefully read this prospectus and all of the information contained in the documents incorporated by reference in this prospectus, as well as the additional information described under the headings &#8220;Where You Can Find More Information.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference in this prospectus, on the other hand, you should rely on the information in this prospectus, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in this prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have not, and the selling stockholders have not, authorized anyone to provide you with any information or to make any representations other than that contained in or incorporated by reference in this prospectus, any prospectus supplement or in any related free writing prospectus filed by us with the Securities and Exchange Commission. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is accurate only as of the date of that free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed materially since those dates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">References in this prospectus to &#8220;our company,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;we&#8221; and similar terms refer to Brooklyn ImmunoTherapeutics, Inc. and not, unless the context otherwise requires, subsidiaries of Brooklyn ImmunoTherapeutics, Inc.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless the context otherwise requires, this prospectus reflects a one-for-two reverse split of common stock effective as of March 25, 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our logo design is our trademark. This prospectus also includes trademarks, trade names and service marks that are the property of other organizations. For convenience, our logo appears in this prospectus without the &#8482; symbol, but those uses are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights to this trademark.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">ii<br></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20001244x1_s1_104-sum_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPS"><!--Anchor--></a>PROSPECTUS SUMMARY</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This summary highlights, and is qualified in its entirety by, the more detailed information included elsewhere or incorporated by reference in this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the entire prospectus, especially as described in &#8220;Risk Factors,&#8221; before deciding to invest in common stock.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Overview</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. We are seeking to develop IRX-2, a novel cytokine-based therapy, to treat patients with cancer. IRX-2 active constituents, namely Interleukin-2 and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells, unlike existing cancer therapies, which rely on targeting the cancer directly. We also are exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using gene-editing cell-therapy technology through a license with Factor Bioscience Limited, or Factor, and through our acquisition of Novellus, Inc. and Novellus Therapeutics Limited, or Novellus, Ltd.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Acquisition of Novellus</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;16, 2021, we and our newly formed, wholly owned subsidiary Brooklyn Acquisition Sub, Inc. entered into an agreement and plan of acquisition, or the Acquisition Agreement, with (a) Novellus LLC, (b) Novellus, Inc., the sole equity holder of Novellus, Ltd. and, prior to the closing under the Acquisition Agreement, a wholly owned subsidiary of Novellus, LLC, and (c) a seller representative. Novellus, Ltd. is a pre-clinical stage biotechnology company organized under the laws of Ireland that is developing engineered cellular medicines using its licensed, patented non-immunogenic mRNA, high-specificity gene editing, mutation-free and footprint-free cell reprogramming and serum-insensitive mRNA lipid delivery technologies.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The closing of the transaction contemplated by the Acquisition Agreement, or the Acquisition, was held contemporaneously with the execution and delivery of the Acquisition Agreement. At the closing:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We acquired all of the outstanding equity interests of Novellus, Inc. as the result of the merger of Brooklyn Acquisition Sub, Inc. with and into Novellus, Inc., following which Novellus, Inc., as the surviving corporation, became our wholly owned subsidiary and Novellus Ltd. became our indirectly owned subsidiary.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We acquired 25.0% of the total outstanding equity interests of NoveCite, Inc., a corporation focused on developing an MSC product for patients with acute respiratory distress syndrome, including from COVID-19.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We delivered consideration for the Acquisition totaling approximately $124.0&#160;million, which consisted of (a) $22.8&#160;million in cash and (b) 7,022,230 shares of common stock, which under the terms of the Acquisition Agreement were valued at a total of $102.0&#160;million, based on a price of $14.5253 per share.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Acquisition Agreement contains customary representations, warranties and certain indemnification provisions. A total of 740,766 of the shares issued as consideration have been placed in escrow for a period of up to 12 months in order to secure indemnification obligations to us under the Acquisition Agreement. The Acquisition Agreement also contains non-competition and non-solicitation provisions pursuant to which Novellus LLC has agreed not to engage in certain competitive activities for a period of five years following the closing, including customary restrictions relating to employees. No employees of Novellus Ltd. or Novellus, Inc. prior to the Acquisition continued their employment, or were otherwise engaged by us, following the Acquisition.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the Acquisition, the co-founders of Novellus, Ltd. entered into lock-up agreements with respect to 3,377,690 of the shares received in the Acquisition, and our Chair of the Board of Directors and its Chief Executive Officer and President entered into identical lock-up agreements with respect to their current holdings of our stock. Each lock-up agreement extends for a period of three years, <font style="font-style: italic;">provided</font> that up to 75% of the shares of common stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on our principal stock exchange, now The Nasdaq Global Market, exceeds specified thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20001244x1_s1_104-sum_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The completion of the acquisition of Novellus, Ltd. relieves our wholly owned subsidiary Brooklyn ImmunoTherapeutics LLC, or Brooklyn LLC, from potential obligations to pay Novellus, Ltd. certain upfront fees, clinical development milestone fees and post-registration royalties under the License Agreement. The agreement with Factor under the exclusive license agreement dated as of April&#160;26, 2021, or the License Agreement, that Brooklyn LLC entered into with Novellus and Factor, which grants Brooklyn LLC exclusive rights to develop certain next-generation mRNA gene editing and cell therapy products, remains unchanged.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;16, 2021, in connection with the Acquisition, we entered into a registration rights agreement with the selling stockholders pursuant to which we have filed the registration statement of which this prospectus forms a part to register for resale under the Securities Act of 1933, as amended, or the Securities Act, a total of 6,281,454 shares of common stock that have been issued to the selling stockholders under the Acquisition Agreement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Risks Related to Our Business</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed in &#8220;Risk Factors&#8221; and include the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We are substantially dependent on the success of our internal development programs, and our product pipeline candidates may not successfully complete clinical trials, receive regulatory approval or be successfully commercialized.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our product candidates and those of any collaborators will need to undergo preclinical and clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for which there is a high risk of failure. If preclinical or clinical trials of our or their product candidates fail to satisfactorily demonstrate safety and efficacy to the U.S. Food and Drug Administration, the European Medicines Agency and any other comparable regulatory authority, additional costs may be incurred or delays experienced in completing, the development of these product candidates, or their development may be abandoned.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may not generate the expected benefits of our acquisition of Novellus, and the acquisition could disrupt our ongoing business, distract our management and increase our expenses.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If we fail to maintain orphan drug exclusivity for IRX-2 or we fail to obtain or maintain such exclusivity for any future drug candidate we may license, our competitors may sell products to treat the same conditions, and our revenues would be significantly adversely affected.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We own only a 25% interest in NoveCite, Inc., and that interest may be diluted unless we invest additional funds.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We face business disruption and related risks resulting from the recent pandemic of the novel coronavirus (COVID-19), which could have a material adverse effect on our business plan.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We have a limited operating history and have never generated any product revenue.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our business is dependent on the successful development, regulatory approval and commercialization of IRX-2, one of our product candidates.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Clinical studies required for our product candidates are expensive and time-consuming, and their outcome is uncertain.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We do not have, and may never obtain, the regulatory approvals we need to market our product candidates.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20001244x1_s1_104-sum_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Gene editing product candidates we may develop based on our exclusive license agreement with Novellus Therapeutics Limited and Factor Bioscience Limited are based on new technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if we are able to obtain such approval.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The U.S. Food and Drug Administration, the U.S. National Institutes of Health and the European Medicines Agency have demonstrated caution in their regulation of gene therapy treatments, and ethical and legal concerns about gene therapy and genetic testing may result in additional regulations or restrictions on the development and commercialization of such products, which may be difficult to predict.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may be unable to successfully scale up manufacturing of IRX-2 in sufficient quality and quantity, which may delay or prevent us from commercializing the product even if approved for marketing by the U.S. Food and Drug Administration or other regulatory agencies.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We will require substantial additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of any of our product candidates.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Corporate Information</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We incorporated under the laws of the State of Delaware in 1984. We changed our name from our initial name Alroy Industries, Inc. to NTN Communications, Inc. in 1985, and then to NTN Buzztime, Inc. in 2005 and to Brooklyn ImmunoTherapeutics, Inc. on March 25, 2021. Our principal executive office is located at 140 58th Street, Suite 2100, Brooklyn, New York 11220, and our telephone number is (212) 582-1199. Our website address is <font style="font-style: italic;">www.brooklynitx.com</font>. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Implications of Being a Smaller Reporting Company</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are a &#8220;smaller reporting company&#8221; because the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either (a) the market value of our stock held by non-affiliates is less than $250 million or (b) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. We may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to public companies that are not smaller reporting companies.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The Offering </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Common stock offered<font style="font-weight: normal; padding-left: 0.84pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">All of the shares offered by this prospectus are being sold by the selling stockholders. The selling stockholders consist of the former owners or beneficial owners of Novellus, Inc., who acquired their offered shares in connection with our acquisition of Novellus Inc., the parent of Novellus Therapeutics Limited, in July 2021.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Selling stockholders<font style="font-weight: normal; padding-left: 1.41pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">See &#8220;Principal and Selling Stockholders&#8221; on page <a href="#tPSS">12</a>.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of proceeds<font style="font-weight: normal; padding-left: 1.38pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">We will not receive any proceeds from the sale of common stock by the selling stockholder pursuant to this prospectus.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Nasdaq Global Market symbol<font style="font-weight: normal; padding-left: 5.65pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">&#8220;BTX&#8221;</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_105-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Investing in common stock involves a high degree of risk. Before acquiring any such shares of common stock, you should carefully consider the risks described below and the risk factors incorporated on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form&#160;8-K filed by us, and all other information contained or incorporated by reference into this prospectus, as updated by our filings under the Securities Exchange Act of 1934. If any of the risks described in our filings incorporated by reference in this prospectus occur, our business, financial condition, results of operations and future growth prospects could be harmed. In these circumstances, the market price of common stock could decline, and you could lose all or part of your investment.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Risks Relating to Ownership of Common Stock</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The market price of common stock historically has been and likely will continue to be highly volatile, which could result in substantial losses for investors purchasing our shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The market price for common stock historically has been highly volatile, and the market for common stock has from time to time experienced significant price and volume fluctuations, based both on our operating performance and for reasons that appear to us unrelated to our operating performance. For example, on November 16, 2021, the closing sale price of the common stock as reported on The Nasdaq Global Market was $7.72. Since March 26, 2021, the interday trading price of common stock has varied between a low of $3.59 on April 1, 2021 and a high of $80.67 on May 3, 2021. During this time, we did not make any announcements regarding our financial condition or results of operations. We may continue to incur rapid and substantial increases or decreases in the price of common stock in the foreseeable future that are do not coincide in timing with the disclosure of news or developments by us.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">In addition, the market price of common stock may fluctuate significantly in response to several factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the level of our financial resources;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcements of entry into or consummation of a financing;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">announcements of new products or technologies, commercial relationships or other events by us or our competitors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">announcements of difficulties or delays in entering into commercial relationships with our partners or customers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">changes in securities analysts&#8217; estimates of our financial performance or deviations in our business and the trading price of common stock from the estimates of securities analysts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fluctuations in stock market prices and trading volumes of similar companies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">additional shares of common stock being sold into the market by us or our existing stockholders or the anticipation of such sales;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">discussion of us or our stock price by the financial press and in online investor communities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">lawsuits threatened or filed against us;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to maintain compliance with any of The Nasdaq Global Market continued listing standards;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">commencement of delisting proceedings by The Nasdaq Global Market; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions or departures of key personnel.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The realization of any of the foregoing could have a dramatic and adverse impact on the market price of common stock.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Future sales of substantial amounts of common stock in the public market, or the anticipation of such sales, could have a material adverse effect on then-prevailing market prices.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of November 8, 2021, there were (a) 3,598,048 shares of common stock reserved for issuance upon the exercise of outstanding stock options with exercise prices ranging from $7.94 to $21.35 at weighted average exercise price of $8.60, (b) 221,640 outstanding restricted stock units with a weighted average intrinsic value of $9.31 per share, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_105-risk_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">(c) 8,484,936 shares of common stock reserved for issuance under our Restated 2020 Stock Incentive Plan, (d)&#160;905,627 shares of common stock reserved for issuance under our 2021 Inducement Equity Incentive Plan, and (e) 156,112 shares of outstanding Series A convertible preferred stock outstanding which were then convertible into approximately 42,165 shares of common stock, and (f) 445,627 shares reserved for issuance to Lincoln Park Capital Fund, LLC . Registration statements registering the shares of common stock underlying the outstanding options, restricted stock units, and the shares issuable to Lincoln Park Capital Fund, LLC are currently effective. Generally, the shares of common stock issuable upon conversion of Series A convertible preferred stock, which the holders may do at any time, may be sold under Rule 144 of the Securities Act of 1933, or the Securities Act. Accordingly, a significant number of shares of common stock could be sold at any time. Depending on market liquidity at the time common stock is resold by the holders thereof, such resales could cause the trading price of common stock to decline. In addition, sales by the selling stockholders, including the anticipation of such sales, could make it more difficult for us to obtain future financing. To the extent the trading price of common stock at the time any of our outstanding options are exercised exceeds their exercise price or at the time any of the outstanding shares of Series A convertible preferred stock are converted exceeds their conversion price, such exercise or conversion will have a dilutive effect on our stockholders.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">We can provide no assurance that claims will not be made to challenge the validity of the ratification of the filing and effectiveness of the certificate of amendment to our restated certificate of incorporation filed with the Secretary of State of the State of Delaware on March 25, 2021 with respect to the increase in the number of authorized shares of common stock pursuant to Section 204 of the Delaware General Corporation Law.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;3, 2021, our stockholders approved the ratification, which we refer to as the Share Increase Ratification, of the amendment to our restated certificate of incorporation filed with the Secretary of State of the State of Delaware on March 25, 2021, which effected an increase in the number of authorized shares of common stock by 85,000,000, from 15,000,000 shares to 100,000,000 shares, and which we refer to as the Share Increase Amendment. We subsequently filed a certificate of validation with respect to the Share Increase Amendment with the Secretary of State of the State of Delaware, which we refer to as the Certificate of Validation, on September&#160;3, 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Even though we filed the Certificate of Validation, any claim that (i) the increase in the number of authorized shares of common stock and related issuance of such shares ratified pursuant to the Share Increase Ratification is void or voidable due to a failure of authorization, or (ii) the Delaware Court of Chancery should declare in its discretion that the Share Increase Ratification not be effective or be effective only on certain conditions, which we refer to collectively as the Subsequent Claims, may still be brought within 120 days from the time that the filing of the Certificate of Validation with the Secretary of State of the State of Delaware becomes effective in accordance with the DGCL.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We can provide no assurance that Subsequent Claims will not be made within the available time period for making such claims or what the resolution of such Subsequent Claims would be. If Subsequent Claims are made, it could have a material adverse effect on our liquidity, which could result in our filing for bankruptcy or an involuntary petition for bankruptcy being filed against us.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Raising additional capital may cause dilution to our existing stockholders and may restrict our operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We may raise additional capital at any time and may do so through one or more financing alternatives, including public or private sales of equity or debt securities directly to investors or through underwriters or placement agents. See &#8220;Our ability to raise capital may be limited by applicable laws and regulations.&#8221; Raising capital through the issuance of common stock (or securities convertible into or exchangeable or exercisable for shares of common stock) may depress the market price of common stock and may substantially dilute our existing stockholders. In addition, our board of directors may issue preferred stock with rights, preferences and privileges senior to those of the holders of common stock. Debt financings could involve covenants that restrict our operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens or make investments and may, among other things, preclude us from making distributions to stockholders (either by paying dividends or redeeming stock) and taking other actions beneficial to our stockholders. In addition, investors could impose more one-sided investment terms on companies that have or are perceived to have limited remaining funds or limited ability to raise additional funds. The lower our cash balance, the more difficult it is likely to be for us to raise additional capital on commercially reasonable terms, or at all.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_105-risk_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Delaware law and provisions in our charter and bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain provisions of our certificate of incorporation could make it more difficult for a third party to acquire control of us, even if such a change in control would benefit our stockholders, or to make changes in the board of directors. For example, our certificate of incorporation (a) prohibits stockholders from filling vacancies on the board, calling special stockholder meetings, or taking action by written consent and (b) requires a supermajority vote of at least 80% of the total voting power of our outstanding shares, voting together as a single class, to remove our directors from office or to amend provisions relating to stockholders taking action by written consent or calling special stockholder meetings.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Additionally, our certificate of incorporation and bylaws contain provisions that could delay or prevent a change of control of our company. Some provisions:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">authorize the issuance of preferred stock that can be created and issued by our board of directors without prior stockholder approval, with rights senior to those of the common stock;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">prohibit our stockholders from making certain changes to our bylaws except with 66 2/3% stockholder approval; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">require advance written notice of stockholder proposals and director nominations. These provisions could discourage third parties from taking control of our company. Such provisions may also impede a transaction in which stockholders could receive a premium over then current market prices and your ability to approve a transaction that stockholders might consider to be in their best interest. In addition, we are governed by Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our certificate of incorporation, bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including delaying or impeding a merger, tender offer, or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of common stock to decline.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">Our bylaws designate the state courts of the State of Delaware (or, if no such state court has jurisdiction, the federal district court for the District of Delaware) as the sole and exclusive forum for certain types of actions that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or with our directors, our officers or other employees, or our majority stockholder.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to our company or stockholders, (c) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or amended and restated bylaws, or (d) any action asserting a claim against us governed by the internal affairs doctrine. We do not expect this choice of forum provision will apply to suits brought to enforce a duty or liability created by the Securities Act, the Securities Exchange Act of 1934, or the Exchange Act, or any other claim for which federal courts have exclusive jurisdiction. Although our bylaws contain the choice of forum provision described above, it is possible that a court could rule that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">By becoming a stockholder in our company, you will be deemed to have notice of and have consented to the provisions of our bylaws related to choice of forum. The choice of forum provision in our bylaws may limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or any of our directors, officers, other employees, agents or stockholders, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_105-risk_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">If securities or industry analysts do not publish research or reports about us, our business or our market, or if they publish negative evaluations of common stock or the stock of other companies in our industry, the price of our stock and trading volume could decline.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The trading market for common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade the common stock or publish inaccurate or unfavorable research about our business, the common stock price would likely decline. In addition, if one or more of these analysts ceases coverage of the common stock or fails to publish reports about the common stock on a regular basis, we could lose visibility in the financial markets, which in turn could cause the common stock price or trading volume to decline.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: justify;">Requirements associated with being a public reporting company involve significant ongoing costs and can divert significant company resources and management attention.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market, and other rules and regulations of the Securities and Exchange Commission, or the SEC. We are working with our legal, independent accounting and financial advisors to identify those areas in which changes should be made to our financial and management control systems to manage our growth and our obligations as a public reporting company. These areas include corporate governance, corporate control, disclosure controls and procedures, and financial reporting and accounting systems. We have made, and will continue to make, changes in these and other areas. Compliance with the various reporting and other requirements applicable to public reporting companies will require considerable time, attention of management and financial resources. In addition, the changes we make may not be sufficient to allow us to satisfy our obligations as a public reporting company on a timely basis.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. The reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve as our directors or executive officers, or to obtain certain types of insurance, including director and officer liability insurance, on acceptable terms.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Short sellers of our stock may be manipulative and may drive down the market price of common stock.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Short selling is the practice of selling securities that a seller does not own but rather has borrowed, or intends to borrow, from a third party with the intention of buying identical securities at a later date to return to the lender. A short seller hopes to profit from a decline in the value of the securities between the sale of the borrowed securities and the purchase of the replacement shares, as the short seller expects to pay less in that purchase than it received in the sale. As it is in the short seller&#8217;s interest for the price of the stock to decline, some short sellers publish, or arrange for the publication of, opinions or characterizations regarding the relevant issuer, its business prospects and similar matters calculated to or which may create negative market momentum, which may permit them to obtain profits for themselves as a result of selling the securities short. The use of the Internet, social media, and blogging have allowed short sellers to publicly attack a company&#8217;s credibility, strategy and veracity by means of so-called &#8220;research reports&#8221; that mimic the type of investment analysis performed by legitimate securities research analysts. Issuers with limited trading volumes or substantial retail stockholder bases can be particularly susceptible to higher volatility levels, and can be particularly vulnerable to such short attacks.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Short seller publications are not regulated by any governmental or self-regulatory organization or any other official authority in the United States and are not subject to the certification requirements imposed by the SEC in Regulation Analyst Certification. Accordingly, the opinions they express may be based on distortions of actual facts or, in some cases, outright fabrications. In light of the limited risks involved in publishing such information, and the significant profits that can be made from running successful short attacks, short sellers will likely continue to issue such reports. Short-seller publications may create the appearance or perception of wrongdoing, even when they are not substantiated, and may therefore affect the reputation or perception of our company and management.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">While we intend to strongly defend our public filings against any such short seller attacks, in many situations we could be constrained, for example, by principles of freedom of speech, applicable state law or issues of commercial </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_105-risk_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">confidentiality, in the manner in which we are able to proceed against the relevant short seller. Such short-seller attacks may cause temporary, or possibly long term, declines in the market price of common stock and possible litigation initiated against us. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: justify;">If the common stock were delisted from The Nasdaq Global Market and determined to be a &#8220;penny stock,&#8221; a broker-dealer may find it more difficult to trade common stock and an investor may find it more difficult to acquire or dispose of common stock in the secondary market.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the common stock were delisted or suspended from trading on The Nasdaq Global Market, it may be subject to the so-called &#8220;penny stock&#8221; rules. The SEC has adopted regulations that define a &#8220;penny stock&#8221; to be any equity security that has a market price per share of less than $5.00, subject to certain exceptions, such as any securities listed on a national securities exchange. For any transaction involving a &#8220;penny stock,&#8221; unless exempt, the rules impose additional sales practice requirements on broker-dealers, subject to certain exceptions. If the common stock were delisted and determined to be a &#8220;penny stock,&#8221; a broker-dealer may find it more difficult to trade common stock and an investor may find it more difficult to acquire or dispose of common stock. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_106-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tFLS"><!--Anchor--></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This prospectus and the information incorporated by reference in this prospectus include &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934. These statements are based on expectations, estimates, forecasts and projections about the industry in which we operate and the beliefs and assumptions of management. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;goals,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;hypothesize,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this prospectus and the information incorporated by reference in this prospectus include statements about:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our plans to develop and commercialize IRX-2 and other product candidates, including the potential benefits thereof;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ongoing and future clinical trials for IRX-2, whether conducted by us or by any future collaborators, including the timing of initiation of these trials and of the anticipated results;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our expectation of the opportunities to advance oncology, blood disorders and monogenic disease therapies using gene-editing and cell therapy technology through a license with Factor Bioscience Inc and through our acquisition of Novellus, Inc. and Novellus, Ltd. in July 2021, and our ability to take advantage thereof;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents and investments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing of and our ability to obtain and maintain marketing approvals for our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our commercialization, marketing and manufacturing capabilities and strategy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our intellectual property position and strategy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to identify additional product candidates with significant commercial potential;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our plans to enter into collaborations for the development and commercialization of product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential benefits of any future collaboration;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developments relating to our competitors and our industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of government laws and regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the impact the coronavirus pandemic will have on the timing of our clinical development and operations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to continue as a going concern;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to maintain our listing on The Nasdaq Global Market.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in our forward-looking statements. We have included important factors in the cautionary statements included, or incorporated by reference, in this prospectus, particularly in &#8220;Risk Factors,&#8221; that we believe could cause actual results or events to differ materially from our forward-looking statements. You should also carefully review the risk factors and cautionary statements described in the other documents we file from time to time with the SEC that are incorporated in this prospectus by reference, specifically our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments to which we may be a party.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_106-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">You should read this prospectus, the documents incorporated by reference in this prospectus and the documents that we have filed as exhibits to the registration statement of which this prospectus forms a part completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this prospectus and incorporated by reference in this prospectus are made as of the respective dates thereof, and we do not assume any obligation to update any forward-looking statements except as required by applicable law.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_106-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUP"><!--Anchor--></a>USE OF PROCEEDS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">All of the shares of common stock offered by this prospectus are being offered by the selling stockholders. For information about the selling stockholders, see &#8220;Principal and Selling Stockholders.&#8221; We will not receive any proceeds from the sale of shares by the selling stockholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The selling stockholders will pay any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the offered shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including all registration and filing fees and fees and expenses of our counsel and our accountants.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_106-fls_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPSS"><!--Anchor--></a>PRINCIPAL AND SELLING STOCKHOLDERS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We issued the shares of common stock covered by this prospectus to the former owners or beneficial owners of Novellus, Inc., in connection with our acquisition of Novellus Inc., the parent of Novellus Therapeutics Limited in July 2021. We are filing the registration statement of which this prospectus forms a part pursuant to the provisions of the registration rights agreement we entered into with the selling stockholders on July&#160;16, 2021. The selling stockholders may, from time to time, offer and sell pursuant to this prospectus up to 6,281,454 shares of common stock that we issued to the selling stockholders in connection with our acquisition of Novellus, Inc. The selling stockholders may sell some, all or none of the shares of common stock acquired in connection with the acquisition. We cannot estimate or predict how long the selling stockholders will hold shares of common stock before selling them, and we have no agreements, arrangements or understandings with the selling stockholders regarding the sale of any of the shares. See &#8220;Plan of Distribution.&#8221;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares of common stock as well as any shares that the stockholder has the right to acquire by January 7, 2022 (sixty days after November 8, 2021) through the exercise or conversion of a security or other right. The percentages of shares of common stock owned are based on 52,043,818 shares of common stock outstanding as of November 8, 2021. The information in the table below with respect to the selling stockholders has been obtained from the selling stockholders. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The table below sets forth, to our knowledge, information concerning the beneficial ownership of shares of common stock as of November 8, 2021 by:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the selling stockholders;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each person known to us to be a beneficial owner of more than five percent of the outstanding shares of common stock;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of our directors and executive officers; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of our directors and executive officers as a group.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We may amend or supplement this prospectus from time to time in the future to update or change this selling stockholders list and the securities that may be resold. Unless otherwise indicated below, the address of each beneficial owner listed in the table below is c/o Brooklyn ImmunoTherapeutics, Inc., 140 58th Street, Suite 2100, Brooklyn, New York 11220.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468.3pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares Beneficially Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Before Offering</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 15.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares to be Sold <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pursuant to Offering</div></td><td class="gutter" rowspan="2" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares Beneficially Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After Offering</div></td></tr><tr class="header"><td style="width: 41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage</div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Selling Stockholders</u><br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael J. Grant<font style="padding-left: 0.92pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 12.5pt;">32,500</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 12.5pt;">32,500</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;%</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Richard E. Grant<font style="padding-left: 4.81pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 12.5pt;">32,500</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 12.5pt;">32,500</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Robert E. Grant<font style="padding-left: 4.25pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 7.5pt;">185,000</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 7.5pt;">185,000</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leonard Mazur<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">1,815,362 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 4.63pt;">3.5%</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;">1,815,362</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Novellus LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(2)</sup><font style="padding-left: 3.69pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">4,216,092 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 4.63pt;">8.2</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;">4,216,092</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Directors and Executive Officers</u><br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Cherington<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">5,894,193</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;">11.3%</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">5,894,193</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;">11.3</div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kevin D&#8217;Amour<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Howard J. Federoff <font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Luba Greenwood<font style="padding-left: 3.97pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 12.5pt;">50,032</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 12.5pt;">50,032</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ronald Guido<font style="padding-left: 2.29pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 7.87pt;">102,112</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 7.87pt;">102,112</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sandra M. Gurrola<font style="padding-left: 2.59pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 17.5pt;">8,203</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 17.5pt;">8,203</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dennis H. Langer<font style="padding-left: 1.48pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lynn Sadowski Mason<font style="padding-left: 1.18pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 12.5pt;">94,333</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 12.5pt;">94,333</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 17.13pt;">*</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Erich Mohr<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jay Sial<font style="padding-left: 2.29pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Roger Sidhu<font style="padding-left: 3.4pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.43pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_106-fls_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468.3pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares Beneficially Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Before Offering</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 15.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares to be Sold <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pursuant to Offering</div></td><td class="gutter" rowspan="2" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares Beneficially Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After Offering</div></td></tr><tr class="header"><td style="width: 41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage</div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allen Wolff<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 2.49pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.43pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 7.13pt;">&#8212;</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">All executive officers and directors as a group (11 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 0.59pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">6,148,781</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;">11.8</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">6,148,781</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;">11.8</div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Additional 5% Stockholders</u><br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">George P. Denny III<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup> <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">P.O. Box 130130 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Boston, Massachusetts 02113<font style="padding-left: 4.63pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">4,832,992</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 4.63pt;">9.3</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.43pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">4,832,992</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 4.63pt;">9.3</font></div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">John Halpern<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">346 Seabreeze Avenue <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Palm Beach, Florida 33480<font style="padding-left: 2.59pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">4,780,307</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 4.63pt;">9.2</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.43pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">4,780,307</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 4.63pt;">9</font>.2</div></td></tr><tr><td style="width: 41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nicholas J. Singer<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">1395 Brickell Avenue <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Suite 800 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Miami, Florida 33131<font style="padding-left: 4.8pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">3,791,983</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.51pt; text-align: left;"><font style="padding-left: 4.63pt;">7.3</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 31.43pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.28pt; text-align: left;">3,791,983</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.52pt; text-align: left;"><font style="padding-left: 4.63pt;">7.3</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 16pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Less than 1%</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Matthew Angel and Christopher Rohde may be deemed to be beneficial owners of all of the shares of common stock owned by Novellus LLC. Messrs. Angel and Rohde have shared voting and investment power over the shares being offered under this prospectus.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Shares of common stock owned by Novellus LLC include (a) 2,580,663 shares intended for distribution to Factor Bioscience, Inc., (b) 623,115 shares intended for distribution to Matthew Angel and (c) 902,831 shares intended for distribution to Christopher Rohde. Factor Biosciences, Inc. and Messers. Angel and Rohde have entered into lock-up agreements with respect to 3,377,690 shares of common stock covered by this prospectus. Each lock-up agreement extends for a period of three years, provided that up to 75% of the shares of common stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on The Nasdaq Global Market stock exchange exceeds specified thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Shares include Series A convertible preferred stock convertible into a total of 19,196 shares of common stock.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Mr. Wolff resigned from his position as our Chief Executive Officer effective as of March 25, 2021. Mr. Wolff is not included in the beneficial ownership of all executive officers and directors as a group.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Based on a Form 4 filed on August&#160;20, 2021 by Mr. Denny. Shares include (a) 4,775,117 shares held by Denny Family Partners II, LLC and (b) 34,585 shares of common stock and shares of Series A 10% convertible preferred stock convertible into 19,196 shares of common stock held by George P. Denny Trust 6/11/81. Mr. Denny has sole voting and dispositive power with respect to 4,094 shares of common stock, and he shares voting and dispositive power with respect to the 4,775,117 shares held by Denny Family Partners II, LLC and the 34,585 George P. Denny Trust 6/11/81. Mr. Denny disclaims beneficial ownership of the shares held by Denny Family Partners II, LLC and George P. Denny Trust 6/11/81 except to the extent of his pecuniary interest therein.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Based on a Form 3 filed with the SEC on May 18, 2021 by Mr. Halpern. Shares include 4,776,213 shares for which Mr. Halpern disclaims beneficial ownership consisting of (a) 2,442,323 shares held by a limited liability company with a family member manager, (b) 2,300,828 shares held by a family trust of which Mr. Halpern is a trustee, (c) 30,192 shares held by a limited liability company with an independent manager, and (d) 2,870 shares held by a trust with an independent trustee.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Based on a Schedule 13D filed with the SEC on April 30, 2021 by Mr. Singer. Shares consist of 1,900,452 shares held by Purchase Capital LLC and 1,891,531 shares held by Pacific Premier Trust as Custodian for the benefit of Mr. Singer.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_107-dcs_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDCS"><!--Anchor--></a>DESCRIPTION OF CAPITAL STOCK</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following description of our capital stock is intended as a summary only and therefore is not complete. This description is based upon, and is qualified by reference to, our certificate of incorporation and bylaws, each as amended from time to time, and by applicable provisions of the Delaware General Corporation Law. You should read our certificate of incorporation and bylaws, which are filed as exhibits to the registration statement of which this prospectus forms a part, for the provisions that are important to you.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.005 per share, and 1,000,000 shares of preferred stock, par value $0.005 per share. A total of 156,112 shares of preferred stock have been designated as Series A convertible preferred stock. The following description of our capital stock and provisions of our certificate of incorporation and bylaws are summaries and are qualified by reference to our certificate of incorporation and bylaws. As of November 8, 2021, 52,043,818 shares of common stock were outstanding and 156,112 shares of Series A convertible preferred stock were outstanding. See &#8220;Risk Factors&#8212;We can provide no assurance that claims will not be made to challenge the validity of the ratification of the filing and effectiveness of the certificate of amendment to our restated certificate of incorporation filed with the Secretary of State of the State of Delaware on March&#160;25, 2021 with respect to the increase in the number of authorized shares of common stock pursuant to Section 204 of the Delaware General Corporation Law.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Common Stock</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Voting Rights.<font style="font-style: normal;"> Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote </font><font style="font-style: normal;">of the stockholders, including the election of directors. Votes may be cast in person or by proxy. Stockholders do not </font><font style="font-style: normal;">have cumulative voting rights with respect to election of directors.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dividends.<font style="font-style: normal;"> Holders of common stock are entitled to receive proportionately any dividends as may be declared and </font><font style="font-style: normal;">paid on common stock from funds lawfully available therefor as and when determined by the board of directors, </font><font style="font-style: normal;">subject to any preferential dividend rights of outstanding preferred stock.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Liquidation and Dissolution.<font style="font-style: normal;"> In the event of our liquidation or dissolution, the holders of common stock are entitled </font><font style="font-style: normal;">to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other </font><font style="font-style: normal;">liabilities and subject to the prior rights of any outstanding preferred stock.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other Rights.<font style="font-style: normal;"> Holders of common stock have no preemptive, subscription, redemption or conversion rights. The </font><font style="font-style: normal;">rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the </font><font style="font-style: normal;">rights of the holders of shares of any series of preferred stock. Outstanding shares of common stock are </font><font style="font-style: normal;">non-assessable. Holders of common stock are not, and will not be, subject to any liability as stockholders.</font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Series A Convertible Preferred Stock</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Voting Rights.<font style="font-style: normal;"> Series A convertible preferred stock has no voting rights.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Dividends.<font style="font-style: normal;"> The holders of Series A convertible preferred stock are entitled to receive cumulative dividends of $0.10 </font><font style="font-style: normal;">per share per annum, payable semiannually in equal installments of $0.05 per share on June 1 and December 1 of </font><font style="font-style: normal;">each year.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Liquidation and Dissolution.<font style="font-style: normal;"> Upon liquidation, dissolution and winding up, each share of Series A convertible </font><font style="font-style: normal;">preferred stock will have preference over common stock to the extent of $1.00 per share, but will not otherwise be </font><font style="font-style: normal;">entitled to share in the proceeds of any liquidation, dissolution or winding up. The preference or subordination of the </font><font style="font-style: normal;">rights of Series A convertible preferred stock with respect to any other class of stock, or any other series of preferred </font><font style="font-style: normal;">stock, shall be as stated in the instrument defining the rights of such other class or series.</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Conversion Rights.<font style="font-style: normal;"> Shares of Series A convertible preferred stock are convertible at any time at the option of the </font><font style="font-style: normal;">holder into a number of duly authorized, validly issued, fully paid and nonassessable shares of common stock equal </font><font style="font-style: normal;">to the number of shares of Series A convertible preferred stock surrendered for conversion divided by the conversion </font><font style="font-style: normal;">rate, which is approximately </font><font style="font-style: normal;">42,165</font><font style="font-style: normal;"> as of November</font><font style="font-style: normal;"> </font><font style="font-style: normal;">8</font><font style="font-style: normal;">, 2021 and which is subject to certain adjustments. No </font><font style="font-style: normal;">fractional shares shall be issued upon conversion of Series A convertible preferred stock, and any portion of a share </font><font style="font-style: normal;">of Series A convertible preferred stock that would otherwise be convertible into a fractional share shall be paid in cash </font><font style="font-style: normal;">in the amount of the liquidation preference of the fractional share. No payment or adjustment shall be made upon any </font><font style="font-style: normal;">conversion on account of any cash dividends on the common stock issued upon such conversion.</font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_107-dcs_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Provisions of Our Certificate of Incorporation and Bylaws and Delaware General Corporation Law may have Anti-Takeover Effects</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our certificate of incorporation and bylaws and the Delaware General Corporation Law contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids and are designed in part to encourage persons seeking to acquire control of us to first negotiate with the board of directors.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 20pt; text-align: left;">Number of Directors; Vacancies</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our certificate of incorporation provides that the number of directors is established by the board of directors, which may delay the ability of stockholders to change the composition of a majority of the board. The board has the exclusive right to elect a director to fill any vacancy or newly created directorship.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 20pt; text-align: left;">Removal of Directors</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A director may be removed only by the affirmative vote of the holders of at least 80% of the voting power of all shares entitled to vote generally in the election of directors, voting together as a single class.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 20pt; text-align: left;">Stockholder Action by Written Consent; Special Meetings</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our certificate of incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Our certificate of incorporation and bylaws also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by the board of directors. These provisions may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 20pt; text-align: left;">Advance Notice Requirements for Stockholder Proposals</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting may consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Delaware Business Combination Statute</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are subject to Section 203 of the Delaware General Corporation Law. Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for three years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with the approval of the board of directors or unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger or consolidation involving us and the &#8220;interested stockholder&#8221; and the sale of more than 10% of our assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Certificate of Incorporation or Bylaws</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any provision of our certificate of incorporation may be amended, altered, changed or repealed in any manner prescribed by law, provided that (a) the affirmative vote of the holders of at least 80% of the voting power of all shares entitled to vote generally in the election of directors, voting together as a single class, is required to alter, amend, or repeal, or adopt any provision inconsistent with Article X of the certificate of incorporation, which contains the prohibition on stockholder action by written consent and the requirement that special meetings be called only by the board of directors, and (b) Article XI of the certificate of incorporation, which provides that, subject to certain exceptions, no purchase by or from any Controlling Person (as defined below) of shares of our stock owned by such </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_107-dcs_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Controlling Person shall be made at a price exceeding the average price paid by such Controlling Person for all shares of our stock acquired by such Controlling Person during the two-year period preceding the date of such proposed purchase unless such purchase is approved by the affirmative vote of not less than a majority of the voting power of the shares of our stock entitled to vote held by Disinterested Stockholders (as defined below), may not be amended without the affirmative vote of not less than a majority of the our stock entitled to vote thereon, provided that if, at the time of such vote, there shall be one or more Controlling Persons, such affirmative vote shall include the affirmative vote in favor of such amendment of not less than a majority of the voting power of the shares of our stock entitled to vote thereon held by Disinterested Stockholders. &#8220;Controlling Person&#8221; means any individual, corporation, partnership, trust, association or other organization or entity (including any group formed for the purpose of acquiring, voting or holding our securities) which either directly, or indirectly through one or more intermediaries, owns, beneficially or of record, or controls by agreement, voting trust or otherwise, at least 10% of the voting power of stock, and such term also includes any corporation, partnership, trust, association or other organization or entity in which one or more Controlling Persons have the power, through the ownership of voting securities, by contract, or otherwise, to influence significantly any of the management, activities or policies of such corporation, partnership, trust, association, other organization or entity. &#8220;Disinterested Stockholders&#8221; means those holders of stock entitled to vote on any matter, none of which is a Controlling Person.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The board may, by majority vote, amend or repeal our bylaws and may adopt new bylaws.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our stockholders may not adopt, amend, or repeal our bylaws or adopt new bylaws except by the vote or written consent of at least 66-2/3% of the voting power of our company.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Exclusive Forum Selection</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to our company or stockholders, (c) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or amended and restated bylaws, or (d) any action asserting a claim against us governed by the internal affairs doctrine. We do not expect this choice of forum provision will apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act, or any other claim for which federal courts have exclusive jurisdiction. Although our bylaws contain the choice of forum provision described above, it is possible that a court could rule that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Authorized but Unissued Shares</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of The Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Stock Options and Restricted Stock Units</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of November 8, 2021, we had outstanding options to purchase 3,598,048 shares of common stock at a weighted average price $8.60 per share and 221,640 outstanding restricted stock units with a weighted average intrinsic value of $9.31 per share.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Listing on The Nasdaq Global Market</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The common stock is listed on The Nasdaq Global Market under the symbol &#8220;BTX.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The transfer agent and registrar for the common stock is Computershare Trust Company, N.A.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_107-dcs_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPD"><!--Anchor--></a>PLAN OF DISTRIBUTION</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The shares covered by this prospectus may be offered and sold from time to time by the selling stockholders. The selling stockholders, which term as used herein includes their transferees, pledgees, donees, assignees or other successors-in-interest, may, from time to time, sell, transfer or otherwise dispose of any or all of their common stock on The Nasdaq Global Market or any other stock exchange, market or trading facility on which such common stock is traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale or at negotiated prices.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The selling stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. The selling stockholders may sell their shares of common stock by one or more of, or a combination of, the following methods:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">block trades in which the broker-dealer will attempt to sell common stock as agent, but may position and resell a portion of the block as principal to facilitate the transaction;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exchange distribution in accordance with the rules of the applicable exchange;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">privately negotiated transactions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in underwriting transactions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">short sales;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">broker-dealers may agree with the selling stockholders to sell a specified number of shares of common stock at a stipulated price;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">distribution to employees, members, limited partners or stockholders of selling stockholders;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a combination of any such methods of sale;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;at the market&#8221; or through market makers or into an existing market for the shares; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other method permitted pursuant to applicable law.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, any shares that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of common stock or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the securities in the course of hedging the positions they assume with selling stockholders. The selling stockholders may also sell common stock short and redeliver the securities to close out such short positions. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of the common stock offered by this prospectus, which common stock such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The selling stockholders may also pledge common stock to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect sales of the pledged shares of common stock pursuant to this prospectus (as supplemented or amended to reflect such transaction).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A selling stockholder may enter into derivative transactions with third parties, or sell common stock not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell shares of common stock covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use shares of common stock pledged by any selling stockholder or borrowed from any selling stockholder or others to settle those sales or to close out any related open borrowings of stock, and may use common stock received from any selling </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_107-dcs_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">stockholder in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, any selling stockholder may otherwise loan or pledge shares of common stock to a financial institution or other third party that in turn may sell the common stock short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In effecting sales, broker-dealers or agents engaged by the selling stockholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the selling stockholders in amounts to be negotiated immediately prior to the sale.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In offering the shares of common stock covered by this prospectus, the selling stockholders and any broker-dealers who execute sales for the selling stockholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits realized by the selling stockholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain of the selling stockholders, or their beneficial owners, have entered into lock-up agreements with respect to 3,377,690 shares of common stock covered by this prospectus. Each lock-up agreement extends for a period of three years, provided that up to 75% of the shares of common stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on The Nasdaq Global Market stock exchange exceeds specified thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In order to comply with the securities laws of certain states, if applicable, the shares of common stock covered by this prospectus must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of securities in the market and to the activities of the selling stockholders and their affiliates. In addition, we will make copies of this prospectus available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities, including liabilities arising under the Securities Act.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the time a particular offer of shares of common stock is made, if required, a prospectus supplement will be distributed that will set forth the number of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have agreed to indemnify the selling stockholders against certain liabilities, including certain liabilities under the Securities Act, the Exchange Act or other federal or state law.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have agreed with the selling stockholders pursuant to our registration rights agreement dated July&#160;16, 2021 to use our commercially reasonable efforts to keep the registration statement of which this prospectus constitutes a part effective until such time as: (i)&#160;all shares of common stock covered by this prospectus have been sold, transferred, disposed of or exchanged in accordance with the registration statement; (ii)&#160;such shares of common stock shall have been otherwise transferred, new certificates for such securities not bearing (or book entry positions not subject to) a legend restricting further transfer shall have been delivered by us and subsequent public distribution of such securities shall not require registration under the Securities Act; (iii)&#160;such shares of common stock have ceased to be outstanding; (iv)&#160;such shares of common stock have been sold to, or through, a broker, dealer, or underwriter in a public distribution or other public securities transaction; or (v)&#160;such shares are eligible to be resold pursuant to Rule 144 under the Securities Act without volume limitation.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The common stock is listed on The Nasdaq Global Market under the symbol &#8220;BTX.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_107-dcs_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLM"><!--Anchor--></a>LEGAL MATTERS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The validity of the shares of common stock offered hereby is being passed upon for us by K&amp;L Gates LLP, Boston, Massachusetts.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tEXP"><!--Anchor--></a>EXPERTS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The consolidated financial statements of NTN Buzztime, Inc. (now known as Brooklyn ImmunoTherapeutics, Inc.) as of December 31, 2020 and 2019 and for each of the years in the two-year period ended December 31, 2020 have been audited by Baker Tilly US, LLP, an independent registered public accounting firm, as stated in their report thereon (which report expresses an unqualified opinion and includes an explanatory paragraph relating to NTN Buzztime, Inc.&#8217;s ability to continue as a going concern), incorporated herein by reference, and have been incorporated in this Prospectus and Registration Statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The financial statements of Brooklyn ImmunoTherapeutics LLC (and its predecessor IRX Therapeutics, Inc.) as of December 31, 2020 and 2019 and for each of the two years in the period ended December 31, 2020 have been audited by Marcum LLP, an independent registered public accounting firm, as stated in their report thereon, appearing in Amendment No. 1 on Form 8-K/A dated April 30, 2021, incorporated in this prospectus by reference, in reliance upon such report and upon authority of such firm as experts in auditing and accounting.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tWYCFMI"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Available Information</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We file reports, proxy statements and other information with the Securities and Exchange Commission, or SEC. Information we filed with the SEC can be inspected and copied at the Public Reference Room maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies of this information by mail from the Public Reference Room of the SEC at prescribed rates. Further information on the operation of the SEC&#8217;s Public Reference Room in Washington, D.C. can be obtained by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website at <font style="font-style: italic;">www.sec.gov</font> that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. Copies of certain information we have filed with the SEC are also available on our website at <font style="font-style: italic;">www.brooklynitx.com</font>, but our website is not a part of this prospectus and the information on our website is not incorporated by reference in, or otherwise part of, this prospectus.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This prospectus is part of a registration statement we filed with the SEC and does not contain all of the information contained in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiary and the securities we are offering. Statements in this prospectus concerning any document that we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should review the complete document to evaluate these statements. You may inspect a copy of the registration statement at the SEC&#8217;s Public Reference Room in Washington, D.C. or through the SEC&#8217;s website, as provided above.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Incorporation by Reference</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_107-dcs_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">This prospectus incorporates by reference the documents listed below (File No. 001-11460) and any future filings we make with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, or the Exchange Act, between the date of this prospectus and the termination of the offering of the shares offered by this prospectus, other than the portions of those documents not deemed to be filed:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221005827/form10-k.htm">March 11, 2021</a>;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Quarterly Report on Form 10-Q for the quarters ended March 31, 2021, June&#160;30, 2021 and September&#160;30, 2021, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121017648/brhc10024479_10q.htm">May 17, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121028301/brhc10027925_10q.htm">August&#160;13, 2021</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121037674/brhc10030504_10q.htm">November&#160;12, 2021</a>, respectively;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221001197/form8-k.htm">January 15, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221002556/form8-k.htm">February 4, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221003076/form8-k.htm">February 9, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221004770/form8-k.htm">February 25, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221004937/form8-k.htm">February 26, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221005525/form8-k.htm">March 8, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221006033/form8-k.htm">March 16, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221006655/form8-k.htm">March 23, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_8k.htm">March 31, 2021</a> (as amended by Amendment No. 1 on Form 8-K/A filed on <a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121015352/brhc10023628_8ka.htm">April 30, 2021</a>), <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121012036/brhc10022864_8k.htm">April 7, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121012968/brhc10022998_8k.htm">April 15, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121013151/brhc10023212_8k.htm">April 16, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121014148/brhc10023524_8k.htm">April 23, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121015275/nt10023650x2_8k.htm">April 30, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121016863/brhc10024430_8k.htm">May 11, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121018871/brhc10025183_8k.htm">May 26, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121020543/brhc10025686_8k.htm">June 10, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121021741/brhc10026052_8k.htm">June&#160;21, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121024732/brhc10026994_form8k.htm">July 19, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121024792/brhc10027031_8k.htm">July 19, 2021</a> (as amended by Amendment No. 1 on Form 8-K/A filed on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121033284/brhc10029466_8ka.htm">October&#160;1, 2021</a>), <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121029038/brhc10028241_8k.htm">August&#160;20, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121030987/brhc10028852_8k.htm">September&#160;13, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121031134/brhc10028918_8k.htm">September&#160;14, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121032255/brhc10029142_8k.htm">September&#160;23, 2021</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036121034543/brhc10029784_8k.htm">October&#160;14, 2021</a>; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the description of common stock contained in Exhibit 4.2 to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220004343/ex4-2.htm">March&#160;19, 2020</a>, including any amendments or reports filed for the purpose of updating such description.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A statement contained in a document incorporated by reference into this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or in any other subsequently filed document that is incorporated in this prospectus modifies or replaces such statement. Any statements so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">You may request a copy of these filings, at no cost, by writing or calling us at Brooklyn ImmunoTherapeutics, Inc., 140 58th Street, Suite 2100, Brooklyn, New York 11220, telephone (212) 582-1199.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20001244x1_s1_300-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 126.75pt; text-align: center;"><img style="height: 108px; width: 425px;" src="logo_brooklyn.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">6,281,454 Shares</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Common Stock</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">PROSPECTUS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 216.5pt; text-align: center;">&#8195;&#8195;&#8195;, 2021</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 139.5pt; margin-left: 0pt; text-align: left;">&#8195;</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_301-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; text-align: center;">INFORMATION NOT REQUIRED IN PROSPECTUS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Item 13.&#8195;Other Expenses of Issuance and Distribution.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table sets forth the various expenses to be incurred in connection with the sale and distribution of the securities being registered hereby, all of which will be borne by us (except any underwriting discounts and commissions and expenses incurred by the selling stockholder for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholder in disposing of the shares). All amounts shown are estimates, except for the SEC registration fee. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 5.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SEC registration fee<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">&#8203;</font>4,542</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">11,000</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 2.11pt;"></font></div></td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">60</font>,000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous fees and expenses<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">9,458</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total expenses<font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 5.5%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$85,000</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Item 14.&#8195;Indemnification of Directors and Officers.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its directors for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of the Delaware General Corporation Law or obtained an improper personal benefit. Our certificate of incorporation provides that none of our directors shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except for liability (a) for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) under section 174 of the Delaware General Corporation Law, or (d) for any transaction from which the director derived an improper personal benefit.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our certificate of incorporation provides that we will indemnify, in the manner and to the full extent permitted by law, any person (or the estate of any person) who was or is a party, or is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding, and whether civil, criminal, administrative, investigative or otherwise, by reason of the fact that such person is or was our director, officer, employee or agent, or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. Where required by law, the indemnification provided for shall be made only as authorized in the specific case upon a determination in the manner provided by law, that indemnification of the director, officer, employee or agent is proper under the circumstances. We may, to the full extent permitted by law, purchase and maintain insurance on behalf of any such person against any liability which may be asserted against him. To the full extent permitted by law, the indemnification provided shall include expenses (including attorneys&#8217; fees) in any action, suit or proceeding, or in connection with any appeal therein, judgments, fines and amounts paid in settlement, and in the manner provided by law any such expenses may be paid by us in advance of the final disposition of such action, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_301-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">suit or proceeding. The indemnification described herein does not limit our right to indemnify any other person for any such expense to the full extent permitted by law, nor is it exclusive of any other rights to which any person seeking indemnification from us may be entitled under any agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The board of directors has approved a form of indemnification agreement that has been executed by each of our directors and executive officers. In general, these agreements each provide that we will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer of our company or in connection with their service at our request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Item 15.&#8195;Recent Sales of Unregistered Securities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Set forth below is information regarding shares of common stock issued by us within the past three years that were not registered under the Securities Act of 1933. Included is the consideration, if any, we received for such shares and information relating to the section of the Securities Act of 1933, or the rule of the Securities and Exchange Commission, under which exemption from registration was claimed.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April 26, 2021, we entered into a purchase agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which we issued to Lincoln Park an aggregate of 1,127,736 shares of common stock from April 26, 2021 through May&#160;18, 2021, of which (a) 56,041 shares of common stock were issued as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under our April 26, 2021 purchase agreement, and (b) 1,071,695 shares were issued to Lincoln Park pursuant to the purchase agreement for an aggregate purchase price of $20.0 million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On May&#160;26, 2021, we entered into a purchase agreement with Lincoln Park pursuant to which we issued to Lincoln Park an aggregate of 2,424,254 shares of common stock from May 26, 2021 through September&#160;20, 2021, of which (a) 50,000 shares of common stock were issued as consideration for Lincoln Park&#8217;s commitment to purchase shares of common stock under our May 26, 2021 purchase agreement, and (b) 2,374,254 shares were issued to Lincoln Park pursuant to the purchase agreement for an aggregate purchase price of $34.1 million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;16, 2021, we entered into an acquisition agreement to acquire all of the outstanding equity interests of Novellus, Inc., which became our wholly owned subsidiary, and Novellus, Ltd. became our indirectly owned subsidiary. We also acquired 25% of the total outstanding equity interests of NoveCite, Inc. We delivered consideration that included 7,022,230 shares of common stock, which under the terms of the acquisition agreement were valued at a total of $102,000,000, based on a price of $14.5253 per share. The closing of the transaction, including the issuance of the common stock, was held contemporaneously with the execution and delivery of the acquisition agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">No underwriters were involved in the foregoing issuances of securities. The securities described in this Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as set forth in Section 4(a)(2) under the Securities Act of 1933 and/or Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 27-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_301-part2_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Item 16.&#8195;Exhibits and Financial Statement Schedules.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exhibits.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Financial Statement Schedules.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Item 17.&#8195;Undertakings.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned Registrant hereby undertakes:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective Registration Statement; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;">provided, however<font style="font-style: normal;">, that paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the information required to be included </font><font style="font-style: normal;">in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the </font><font style="font-style: normal;">Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as </font><font style="font-style: normal;">amended (the &#8220;Exchange Act&#8221;), that are incorporated by reference in this Registration Statement.</font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">That, for the purposes of determining any liability under the Securities Act, each post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial bona fide offering thereof.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability under the Securities Act to any purchaser,</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 28-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_301-part2_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 80pt; text-align: justify;">securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant&#8217;s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the indemnification provisions described herein, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 29-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_302-exidx_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">EXHIBIT INDEX</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 12.82%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 85.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220015948/ex2-1.htm">2.1+</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Agreement and Plan of Merger and Reorganization, dated August 12, 2020, among Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), BIT Merger Sub, Inc. and Brooklyn ImmunoTherapeutics LLC (incorporated herein by reference to Exhibit 2.1 to the Registration Statement on Form S-4/A filed on January 20, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220015948/ex10-1.htm">2.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Form of Support Agreement among Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), Brooklyn ImmunoTherapeutics LLC and the officers and directors of NTN Buzztime, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on August 14, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220015948/ex10-2.htm">2.3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Form of Support Agreement among Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), Brooklyn ImmunoTherapeutics LLC and certain beneficial holders of Class A membership interests of Brooklyn ImmunoTherapeutics LLC (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on August 14, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000101968713003135/ntn_10q-ex0301.htm">3.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Restated Certificate of Incorporation of Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.) (incorporated herein by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed on August 14, 2013)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315216010919/ex3-1.htm">3.1(a)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Certificate of Amendment to the Restated Certificate of Incorporation of Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), dated June 16, 2016 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 17, 2016)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315217003784/ex3-1.htm">3.1(b)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Certificate of Decrease of the Series A convertible preferred stock of Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), dated April 10, 2017 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on April 12, 2017)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315217006434/ex3-1.htm">3.1(c)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Certificate of Amendment of Restated Certificate of Incorporation of Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), dated June 8, 2017 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on June 9, 2017)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex3-1.htm">3.1(d)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Certificate of Amendment of Restated Certificate of Incorporation of Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), dated March 25, 2021 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on March 31, 2021) </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex3-2.htm">3.1(e)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Certificate of Amendment of Restated Certificate of Incorporation of Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), dated March 25, 2021 (incorporated herein by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on March 31, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex3-3.htm">3.1(f)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Certificate of Amendment of Restated Certificate of Incorporation of Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), dated March 25, 2021 (incorporated herein by reference to Exhibit 3.3 to the Current Report on Form 8-K filed on March 31, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121030987/brhc10028852_ex3-1.htm">3.1(g)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Certificate of Validation of Brooklyn ImmunoTherapeutics, Inc., as filed with the Secretary of State of the State of Delaware on September&#160;3, 2021 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September&#160;13, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121032255/brhc10029142_ex3-2.htm">3.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Amended and Restated Bylaws of Brooklyn ImmunoTherapeutics, Inc. (incorporated herein by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on September&#160;23, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121015372/nt10023650x1_ex4-1.htm">4.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Specimen stock certificate evidencing shares of common stock of Brooklyn ImmunoTherapeutics, Inc. (incorporated herein by reference to Exhibit 4.1 to the Registration Statement on Form S-1 filed on April 30, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121015372/nt10023650x1_ex4-2.htm">4.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Description of registrant&#8217;s securities (incorporated herein by reference to Exhibit 4.2 to the Registration Statement on Form S-1 filed on April 30, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.1&#8225;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of K&amp;L Gates LLP</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220000627/ex10-1.htm">10.1+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Asset Purchase Agreement dated January 13, 2020, between Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.) and Sporcle, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 15, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/forms-4a.htm#aa_002">10.2+</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Asset Purchase Agreement dated September 18, 2020 by and between Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.) and eGames.com Holdings LLC (incorporated herein by reference to Exhibit 2.4(a) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 30-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_302-exidx_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 12.82%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 85.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/forms-4a.htm#gs_001">10.2(a)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Omnibus Amendment and Agreement entered into as of November 19, 2020 by and among eGames.com Holdings LLC, Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), and Fertilemind Management, LLC (incorporated herein by reference to Exhibit 2.4(b) to the Registration Statement on Form S-4/A filed on November 25, 2020) </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315221001197/ex10-1.htm">10.2(b)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Second Omnibus Amendment and Agreement entered into as of January 12, 2021 by and among eGames.com Holdings LLC, Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.), and Fertilemind Management, LLC (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 15, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121030987/brhc10028852_ex99-1.htm">10.3&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Brooklyn ImmunoTherapeutics, Inc. Restated 2020 Stock Incentive Plan (incorporated herein by reference to Exhibit 99.1 to the Current Report on Form 8-K filed on September&#160;13, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-16a.htm">10.4*&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Letter agreement, dated October 30, 2018, between Brooklyn ImmunoTherapeutics LLC and Ronald Guido (incorporated herein by reference to Exhibit 10.16(a) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex10-3.htm">10.4(a)&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Assignment and Assumption of Employment Agreement, dated March 30, 2021, among Brooklyn ImmunoTherapeutics LLC, Brooklyn ImmunoTherapeutics, Inc. and Ronald Guido (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on March 31, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-16b.htm">10.5&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Unit Restriction Agreement, dated as of November 5, 2018, between Brooklyn ImmunoTherapeutics LLC and Ronald Guido (incorporated herein by reference to Exhibit 10.16(b) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-17a.htm">10.6*&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Letter agreement, dated October 30, 2018, between Brooklyn ImmunoTherapeutics LLC and Lynn Sadowski Mason (incorporated herein by reference to Exhibit 10.17(a) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-17b.htm">10.6(a)&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Amendment to letter agreement, dated March 12, 2020, between Brooklyn ImmunoTherapeutics LLC and Lynn Sadowski Mason (incorporated herein by reference to Exhibit 10.17(b) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex10-4.htm">10.6(b)&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Assignment and Assumption of Employment Agreement, dated March 30, 2021, among Brooklyn ImmunoTherapeutics LLC, Brooklyn ImmunoTherapeutics, Inc. and Lynn Sadowski Mason (incorporated herein by reference to Exhibit 10.4 to the Current Report on Form 8-K filed on March 31, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-17c.htm">10.7&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Unit Restriction Agreement, dated as of November 1, 2018, between Brooklyn ImmunoTherapeutics LLC and Lynn Sadowski-Mason (incorporated herein by reference to Exhibit 10.17(c) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121012036/brhc10022864_ex10-1.htm">10.8&#8224;^</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Executive Employment Agreement, dated as of April 1, 2021 and effective as of April 16, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Howard J. Federoff (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 7, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121018871/brhc10025183_ex10-3.htm">10.9&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Brooklyn ImmunoTherapeutics, Inc. 2021 Inducement Stock Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on May&#160;26, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121020543/brhc10025686_ex10-1.htm">10.10&#8224;^</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Executive Employment Agreement, dated as of June&#160;5, 2021 and effective as of June&#160;28, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Kevin D&#8217;Amour (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June&#160;10, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121021741/brhc10026052_ex10-1.htm">10.11&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Executive Employment Agreement, dated as of June&#160;16, 2021 and effective as of June&#160;21, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Sandra Gurrola (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June&#160;21, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121024792/brhc10027031_ex10-1.htm">10.12&#8224;^</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Executive Employment Agreement, dated as of July&#160;6, 2021 and effective as of July&#160;15, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Jay Sial. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on July&#160;19, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121032255/brhc10029142_ex10-1.htm">10.13&#8224;^</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Executive Employment Agreement, effective as of September&#160;20, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Roger Sidhu (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on September&#160;23, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121013151/brhc10023212_ex10-1.htm">10.14&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 16, 2021)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-6<br></div></div></div>
<!--End Page 31-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_302-exidx_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 12.82%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 85.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121037674/brhc10030504_ex10-4b.htm">10.14(a)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Schedule identifying agreements substantially identical to the form of Indemnification Agreement filed as Exhibit 10.14 (incorporated herein by reference to Exhibit 10.4(b) to the Quarterly Report on Form 10-Q filed on November&#160;12, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-19a.htm">10.15+</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">License Agreement, dated as of June 28, 2000, between Brooklyn ImmunoTherapeutics LLC (formerly Immuno-Rx, Inc.), and the University of South Florida Research Foundation, Inc. (incorporated herein by reference to Exhibit 10.19(a) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-19b.htm">10.15(a)+</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Amendment No. 1 to License Agreement, dated June 30, 2009, between Brooklyn ImmunoTherapeutics LLC (formerly Immuno-Rx, Inc.) and the University of South Florida Research Foundation, Inc. (incorporated herein by reference to Exhibit 10.19(b) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-19c.htm">10.15(b)+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Amendment No. 2 to License Agreement, dated June 5, 2012, between Brooklyn ImmunoTherapeutics LLC (IRX Therapeutics, Inc.) and the University of South Florida Research Foundation (incorporated herein by reference to Exhibit 10.19(c) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-23a.htm">10.16+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Lease Agreement, dated September 28, 2015, between Biobat, Inc. and Brooklyn ImmunoTherapeutics LLC (formerly IRX Therapeutics, Inc.) (incorporated herein by reference to Exhibit 10.23(a) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-23b.htm">10.16(a)+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">First Amendment to Lease Agreement, dated September 28, 2015, between Biobat, Inc. and Brooklyn ImmunoTherapeutics LLC (formerly IRX Therapeutics, Inc.) (incorporated herein by reference to Exhibit 10.23(b) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-23c.htm">10.16(b)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Assignment and Assumption of Lease, effective January 14, 2019 between Brooklyn ImmunoTherapeutics LLC (formerly IRX Therapeutics, Inc.) and Brooklyn ImmunoTherapeutics LLC, and consented to by Biobat, Inc., as landlord (incorporated herein by reference to Exhibit 10.23(c) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-23d.htm">10.16(c)+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Second Amendment to Lease Agreement, dated July 24, 2019, between Biobat, Inc. and Brooklyn ImmunoTherapeutics LLC (incorporated herein by reference to Exhibit 10.23(d) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-20.htm">10.17+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Termination and License Agreement, effective as of June 22, 2018, between Celgene and Brooklyn ImmunoTherapeutics LLC (formerly IRX Therapeutics, Inc.) (incorporated herein by reference to Exhibit 10.20 to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-24a.htm">10.18+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Sublease Agreement, dated April 18, 2019, between Brooklyn ImmunoTherapeutics LLC and Nezu Asia Capital Management, LLC (incorporated herein by reference to Exhibit 10.24(a) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-24b.htm">10.18(a)+</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Consent to Sublease and Agreement, dated as of May 13, 2019, among 654 Madison Avenue Associates LP, Brooklyn ImmunoTherapeutics LLC, and Nezu Asia Capital Management, LLC (incorporated herein by reference to Exhibit 10.24(b) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-24c.htm">10.18(b)*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Commencement Date Confirmation Agreement, made as of June 27, 2019, among Brooklyn ImmunoTherapeutics LLC and Nezu Asia Capital Management, LLC (incorporated herein by reference to Exhibit 10.24(c) to the Registration Statement on Form S-4/A filed on November 25, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220006840/ex10-1.htm">10.19</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Paycheck Protection Program Note, dated April 18, 2020, issued by Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.) in favor of Level One Bank (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April&#160;21, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220006840/ex10-2.htm">10.19(a)</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Acknowledgment and Agreement Regarding Loan Forgiveness, dated April 18, 2020, executed by Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.) in favor of Level One Bank (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on April&#160;21, 2020)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex10-1.htm">10.20*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Amended and Restated Royalty Agreement and Distribution Agreement, dated as of March 22, 2021 (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 31, 2021) </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-7<br></div></div></div>
<!--End Page 32-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_302-exidx_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 12.82%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 85.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121015275/nt10023650x2_ex10-1.htm">10.21</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Purchase Agreement, dated as of April 26, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on April 30, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121015275/nt10023650x2_ex10-2.htm">10.22</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Registration Rights Agreement, dated as of April 26, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on April 30, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121015275/nt10023650x2_ex10-3.htm">10.23+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Exclusive License Agreement, dated April 26, 2021, among Novellus Therapeutics Limited, Factor Bioscience Limited and Brooklyn ImmunoTherapeutics LLC (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K filed on April 30, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121018871/brhc10025183_ex10-1.htm">10.24</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Purchase Agreement, dated as of May&#160;26, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on May&#160;26, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121018871/brhc10025183_ex10-2.htm">10.25</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Registration Rights Agreement, dated as of May&#160;26, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on May&#160;26, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121024732/brhc10026994_ex10-1.htm">10.26(a)+*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Agreement and Plan of Acquisition, dated as of July&#160;16, 2021, by and among Brooklyn ImmunoTherapeutics, Inc., Brooklyn Acquisition Sub, Inc., Novellus LLC, Novellus, Inc., and the Sellers&#8217; Representative. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on July&#160;19, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121024732/brhc10026994_ex10-2.htm">10.26(b)+</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Registration Rights Agreement, dated as of July&#160;16, 2021, by and among Brooklyn ImmunoTherapeutics, Inc. and the individuals and entities named therein. (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on July&#160;19, 2021)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20001244x1_ex21-1.htm">21.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Subsidiaries of Brooklyn ImmunoTherapeutics, Inc. </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20001244x1_ex23-1.htm">23.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Baker Tilly US, LLP</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20001244x1_ex23-2.htm">23.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Marcum LLP</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">23.3&#8225;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of K&amp;L Gates LLP (included in Exhibit 5.1)</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOA">24.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Power of Attorney (included on signature page of this registration statement)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 16pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">+<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) or Item 601(b)(2) of Regulation S-K. We hereby undertake to furnish copies of the omitted schedule or exhibit upon request by the Securities and Exchange Commission</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Certain information redacted and replaced with &#8220;[***]&#8221;.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#8224;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Management contract or compensatory plan.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">^<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Certain addenda have been omitted pursuant to Item 601(a)(5) of Regulation S-K. We hereby undertake to furnish copies of the omitted addenda upon request by the Securities and Exchange Commission, provided that we may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for the addenda so furnished.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#8225;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be filed by amendment.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-8<br></div></div></div>
<!--End Page 33-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20001244x1_s1_303-sig_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SIGNATURES</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on November 16, 2021.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Howard J. Federoff</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Howard J. Federoff</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and President</div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;"><a name="tPOA"><!--Anchor--></a>SIGNATURES AND POWER OF ATTORNEY</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Each person whose signature appears below hereby constitutes and appoints Howard J. Federoff and Sandra Gurrola, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 33.33%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Signature</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 41.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 20.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Howard J. Federoff</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer, President and Director <font style="font-style: italic;">(principal executive</font><font style="font-style: italic;"> officer)</font></div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November 16, 2021</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Howard J. Federoff</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Sandra Gurrola</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vice President of Finance<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-style: italic;">(principal financial and accounting officer)</font></div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November 16, 2021</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sandra Gurrola</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Charles Cherington</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November 16, 2021</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Cherington</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Luba Greenwood</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November 17, 2021</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Luba Greenwood</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Dennis H. Langer</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November 16, 2021</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dennis H. Langer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Erich Mohr</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-9<br></div></div></div>
<!--End Page 34-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ny20001244x1_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 7.7.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 21.1</font><br>
    </div>
    <div style="text-align: right;"> <br>
    </div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>BROOKLYN IMMUNOTHERAPEUTICS, INC.</u></div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u> <br>
    </u></div>
  <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Subsidiaries of the Registrant</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0d655c65272a4fb5bd71faf7d544abf5" border="0" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: auto; vertical-align: top; border-bottom: 2px solid black;">
          <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Name of Subsidiary</div>
        </td>
        <td colspan="1" style="width: 30%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        <td style="width: auto; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
          <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Jurisdiction of Incorporation</div>
        </td>
      </tr>
      <tr>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif;">Brooklyn ImmunoTherapeutics LLC</div>
        </td>
        <td colspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif;">Delaware</div>
        </td>
      </tr>
      <tr>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif;">Novellus, Inc.</div>
        </td>
        <td colspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif;">Delaware</div>
        </td>
      </tr>
      <tr>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif;">Novellus Therapeutics, Ltd.</div>
        </td>
        <td colspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
        <td style="width: auto; vertical-align: top;">
          <div style="font-family: 'Times New Roman', Times, serif;">Ireland</div>
        </td>
      </tr>
      <tr>
        <td style="width: auto; vertical-align: top;">&#160;</td>
        <td colspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
        <td style="width: auto; vertical-align: top;">&#160;</td>
      </tr>

  </table>
  <div><br>
  </div>
  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ny20001244x1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 7.7.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;">Exhibit 23.1</font><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; margin-left: 18pt; font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We consent to the incorporation by reference in this Registration Statement on Form S-1 of Brooklyn ImmunoTherapeutics, Inc. (formerly known as NTN Buzztime, Inc.) of our report dated March 11, 2021, relating to the
      consolidated financial statements of NTN Buzztime, Inc. appearing in the Annual Report on Form 10-K of NTN Buzztime, Inc. for the year ended December 31, 2020 (which report expresses an unqualified opinion and includes an explanatory paragraph
      relating to the Company&#8217;s ability to continue as a going concern).</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We also consent to the reference to our firm under the heading &#8220;Experts&#8221; in such Prospectus.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="font-weight: bold;">/S/ BAKER TILLY US, LLP</div>
    <div><br>
    </div>
    <div>San Diego, California</div>
    <div>November 18, 2021
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ny20001244x1_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 7.7.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 23.2</div>
    <div><br>
    </div>
    <div style="text-align: center;"><u>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#8217;S CONSENT</u></div>
    <div><br>
    </div>
    <div style="text-align: justify;">We consent to the incorporation by reference in this Registration Statement of Brooklyn ImmunoTherapeutics, Inc. on Form S-1 of our report dated April 30, 2021, with respect to our audits of the financial statements of
      Brooklyn ImmunoTherapeutics, LLC as of December 31, 2020 and 2019 and for each of the two years in the period ended December 31, 2020 appearing in Amendment No. 1 to Form 8-K/A of Brooklyn ImmunoTherapeutics, Inc. dated April 30, 2021.<font style="font-weight: bold;">&#160;</font>We also consent to the reference to our firm under the heading &#8220;Experts&#8221;<font style="font-weight: bold;">&#160;</font>in the Prospectus, which is part of this Registration Statement.</div>
    <div><br>
    </div>
    <div>/s/ Marcum <font style="font-variant: small-caps;">llp</font></div>
    <div><br>
    </div>
    <div>Marcum <font style="font-variant: small-caps;">llp</font></div>
    <div>New York, NY</div>
    <div>November 18, 2021</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>logo_brooklyn.jpg
<TEXT>
begin 644 logo_brooklyn.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M?_PD M(YM2T^]L8TT[Q!HZB_TQ#)!J=GIWY??\1.?[;14$?"7]F\@XP1HGQ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2^(5ZP>\\>_$;QQXVN6!# S>+/$^J:^_SC[X7^T @/'RJ%   K]]/^","_\
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MM[=-P_K^OO7WDE%1^=$2%$B;B0 N1DD] !U_^L">U24 %%%% !1110 4444
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M.:]+C+B/C',Z?!7$=7BS X;'5,MS&K1J87&QPF'P^+H9GF>6U,3@(1C+E=;
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M=WV=K:G]4]%?+_\ PAW[7?\ T7/X,_\ AA_$/_SXJ/\ A#OVN_\ HN?P9_\
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M@^DA_P ESE__ &3F"_\ 4[,C^N_ ;_DC\=_V/\7_ .H.7!1117\_'[:%%%%
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M?"FO:CXA/AG1)T@;3+/Q%?ZA!$L?B8IYLNIZ?9-<VE@9(K9KI[J*=(_!XHX
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M@/3_ !O%XEM;F?Q<OA^'3%O?#NO'36TV>+4GNGB%N;A;N$9?RL#^AX_LW_\
M!>;'R_\ !0G]F@?7X":%P/3CX:$?J?K7\.^,'#N'QWB%GV*J<4\,9=.J\NYL
M)F.(S>&+H\N5X&*=6.%R;&4ESI*I#EK2O%J]G=+^P?"[.,3@^!\DH0X?SW'1
M@L=;$X.GE3H5%+,,1)N#Q6;86J[7<7S4H^]%VNK-X_\ P<@,!_P3<UA01D_&
MOX3C'?'VK6#P.O2OV4^ 1 ^!?P5!."/A-\.P0>"#_P (AHW!]#[5_)=_P6*^
M#O\ P5%\$?L;:CK_ .U[^UG\&/C-\(8?B9X"MY_!?@7X5Z9X0UZ7Q#<37ZZ%
MJ2:Q:>$- D6TT^47,EU;F[_?JZ)L=00OZ(?"[]G3_@N7>_#+X<WOA;]OO]G+
M1_#5[X$\(7?A[2[SX'Z-<WFEZ#<>'M-ETC3;NZ?X?RFXN;*QDBMKB9GEDFE@
M:5YYBQ:O(Q_#.&GP!PSAWQ;PI3A1XBXEK1Q<\1G?U2O*MA,BA*A1E'(I5G5H
M*E&=55*-*"C5@Z<ZCYU#T\'GV*CQEGU9\-<0SE/).'X/#1AE/MZ*IXK.)1JU
M%_:[H^RK.HXT^2O.?/2J<\(+D<_Z':*_"6/]F[_@O.$ /_!0K]F@D9R?^%#Z
M"V>3SD_#9B?S/H*23]F__@O.<;?^"A/[,QZYS\!M"7TQC_BVRY]^O:OB5PE@
M[V_UVX+MW^L\0>6NO#B_K\/K'Q%C$KKA+B=[:*GD5]>737/UW>Z3TVZ/P_\
MX+(\_P#!1'_@C1CG'[2^D9QSC'Q7^#6<^F*_I&B/#?[Y_D /Y5_$Y_P41^$_
M_!2KPM^UK_P3DT?]H/\ :B^#OQ(^+/B;XUV5A^SWXN\+_#'3_#VC?#CQ?+XZ
M^',%OK'BG38/"FG0^(;"/7[CP[J+VTMAJ0:UTR]@-O(+D1O^Q:?LV_\ !>8
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M=J_SB?\ @A9_RE _9N_Z^/'W_JM?&%?Z.U?Q!])#_DN<O_[)S!?^IV9']=^
MW_)'X[_L?XO_ -0<N"BBBOY^/VT**** "D(R"/4$?G7AG[2_[0'@_P#99^!G
MQ%^/_C^QUO4O!OPRT5->\06?ARWL[K6YK)[^STX+I]O?WVFVDL_GWL/R37L"
ME=QWY !_$D_\',G["0) ^'O[1C8)&1X0\$=C@_\ -0NH/7KSWKZ7).#N*.)*
M%;$Y%D>/S7#T*WL*U7"4?:0I5G"-14YNZY9.$XR2>Z>G6W@9MQ3P[D-:GA\X
MSC Y=7K4_;4J6*JJG.I2YI0YXJS;CSQE&_1JSW5_M7_@JE_P36\$?\% ?@E<
MV&GVFDZ%\?O ^GWUY\(?']V#:JEQY;2W'@KQ-=VUO-<W/@[Q$_R7,/ERMI.I
M-;ZU9@207$%W_G1?$?X;^-OA!X[\5?#+XC^'M1\(^._!.MWN@^)/#FK0-!?Z
M9J5BW[ZVE4Y60&-H[BWN8F:WO+26"\MF>VN(G;^X8_\ !S+^PAC#_#W]HQ<]
M,^$/!'Z?\7"[?UK\)/\ @KE^VS_P3Z_;U@TGXJ_!7P5\6?A_^T=H4UGI>L:S
MXB\&^&;#P_\ $CPIMCA73_%%YI7C34GAUSPZFV[\.:S_ &9>W4]I]JT2=A!]
MBGTW^G/!5^(G"N)7#G$'"^>+AO%3G4PN*J8:4HY/BIQ3<G:;<<!7<8JK&,7[
M"J_;12A*N?S[XKT^!^(\.\^R/B+)GGN&A&%?#4\3",LTPT6DHI-*^,HIMTIM
MKVM*])WDJ37X0%F(QGCG/ SR"IYQD<$@[2,@_-G"X_H&_P""*O\ P5KO_P!D
M#QA8?L^?'KQ%>W/[,_C'4C'HFJ7:SWQ^#7BG4[B61M6MFFF5[;P-K-U,\WBJ
MW1YX=,NY%\06,<2/J]O/_/O1Z\9.#CI@-CY2<A@0#@XQSTK]_P"*.&<JXNR7
M%9)G%#VV&Q$>:G4C:-;"8F*?L<5AJCC+V=:E*S3LXSCS4ZD9PE*+_$N'L_S'
MAC-<-F^5U72Q&'E:=-W]CB:$FO:X;$032G1JI)25TXR49P<9QC)?ZZ^DZI9:
MQIUGJFG7EK?Z?J%K!>V%]9S17%K>65U"D]K=VTT+R136]S#(D\$T;M')#(DB
M$JP8Z-?PQ_\ !*C_ (+KQ?LF?#B^^!7[5%IX_P#B1\.O#%M;/\(?$'AM=-UO
MQ;X4L5 MI? M_;ZSJNBB^\+6T(%UX?N7U&670A!<:0L#:;/ID6F?KF/^#F3]
M@\G"^ OVB&]0OA+P22!ZD?\ "P?7 //>OX3SKP;X]RK-,7@,)D./S?"T*KCA
MLRP-'VF'Q=%ZTZJ]Z].;BTJM*6M.HI1O*/+.7]CY/XJ<&9EEV&QF)SG!97B*
MM->WP.-K*E7P]9:3@[JTX<UW3J1;4X.+M%WBOZ*<C.,C/IWK\R/^"O7[37AK
M]F3]@OX[Z_J>I6]MXF^(?@[6OA'\/M/9T-UJGBOXA:5>:"K6</FQ-*-%TBZU
M/Q!=.K;8;;3'9\[E5OS?\:?\'.'['VF:-=7?@OX._';Q/KXB<6.E:U9>#/"N
MG7$X4>4EUK4?B;Q"]K"7'S2II=Y*@/[N"0@*?Y7/V]?^"A/QW_X*!?$J/QG\
M4]131O"'AZXO%^''PMT.YE'A?P1I]TT(>02-'"^N>(KN."+^U?$6HVIGNWBC
MBLK?2]/2&PA^G\/?!3BO,<_P.*XBRJODV39?B:&+Q4L=:G6QGL*BJ0PF&HQ]
MI4DZTX1C5JRC"G2I2E+G<G",OG>./%GAO!9)C<-D684<VS3&X>MAL/\ 5%.I
MA\,JU-PEB*U=<D+TXS;ITZ<ISE545)0@I37P@!CCCC(..A.>2/G?*DY*D,0P
M((P" %]/<X'N?0>]*<$G P,G R2<9X))ZL1RW;<3CC%;7AGPYKGC+Q)X?\'^
M%].NM7\4>*]9TSPWX<TFR5I+K5-;UR]@TS2].@0*VZ2^O[JVMER8_P#6_P"L
M0\U_<DYQA"=6HU"G3C*I5FW:-.G!.523DVU:$4Y-N3T5V[:G\@PC.I*$(1<Z
ME24(1A%7E*<VHJ*6[;;22[G]TW_!L]X+OO#O[!GC7Q/>6[VZ?$#]HKQMJ^FO
M(FTW>D:%X0\!>%4G! Y UC1]:B1L\Q1(#R,5]7_\%V?^47?[2?\ US^''_JT
M/!U?7W["7[-MM^R5^R9\"_@-&MH=4\#^!-)C\7W5GCR-1\=ZM%_;7C;4H67*
MO!=^)]0U5[7DK'9FVA0^7"E?(/\ P79_Y1=_M)_]<_AQ_P"K0\'5_GA3SBGQ
M!XPX/.:+YJ&/X[RZKAI:>]A89MAJ.&DK:6E0ITY+U/[>GE=3)?"G%9763C7P
M?!N,IXB+=^7$2RRK5Q$;W=^6M4J1\K6Z7/\ ./I\3F&:*=0&>&2.10V=I,<B
MR*K ?PED&<<XR,TRBO\ 1!ZIIZIJS3V:[-=4?Q!^FJ]5L_D>W_'O]HGXP_M+
M>.YOB)\9?&VI>+_$'V"VT?2H[B<IH_AWPY:1A-/\->&M'4+:Z3H>FH,16]O%
M&99Y)+JZ:XNYY;A_$,EB>=S !G/&>>KL  !N())P%SG '2G*I;=@$E5+8 )S
MCD@$# )&0NXJ&;"[@6%?T5_L*_\ !O+\??VA=&\-_$O]HWQ0?V?OAMK,5AJ^
MG^$5TFTU[XJ>(-'NV26.:;3WOH]*\%?;;0^;9W&NIJVK6\<D;7'AN..7GY?/
M.).%N!,JH5LTQ6#RC T8^QP.#HTHQJ55346Z."P="*G4Y4[N-."@M'.2;U^B
MR?(>(N,<QJT\NP^(S7'3:JXO$U:EU34VHNKB\76E:/,U>/M)\T[-04G%H_GR
M\(_-XJ\.A>3_ &YHG Y/_(9TT]![ GZ GI7^N!:$?9+7G_EWA'X^6HQ^?'UK
M\0?!7_!O/_P3<\)6^G-J'@GXE^-=7T^2"X&M^)/BSXMM+F:YMV21))+'PG<>
M&=%"&1-QC32U7!"-YBJN/V2\;^,O#7PS\!^*?''B_4H-&\*>!?"VL^)O$.JW
M#R&#3M!\-Z5<:GJE[(0'FD%K8V<TQ1%>:38%56=U!_CCQF\0\E\1,7P_'(,/
MF2_LQ9E2J/&8:E1E7GCI9?['ZO"EB,1*6N%FFIJ#NXI)MM+^I?"K@?-^!Z6>
MSSNME]LQ_L^I3>$Q%6K&C'!QQOMG7E5P]",=,1!Q<7-6C.]K)OXR_P""AO\
MP4)^$7_!/KX.2^/_ !W<#7/&OB'[=I7PP^&FG3VXU[QMXC@MP^ LLJ?8/#FD
MR2VL_B/79 8M/MIH;>".YU2_TVSN?\\+]K#]LO\ :$_;5^(=S\1/CYXYO?$5
MQ'/.WASPG9M)8^"/!%C,5*Z9X1\.J[6NEQ(J*)-082ZUJ#YN-2U"ZG.\=G_P
M4&_;4\<?MU_M*^-OC+XBO]0@\)PZA>:%\)/"ES,QMO!_P]L=0F?0K$VD+0P+
MJM_ 8M5\1W$96:]UJ6XBG86UO!#%\1'CI^'0?0<G ^I(4=20 37]&>$WA=@.
M"<KP^8YAAZ6(XHQU&-7%XFHHU'ET*L(MY?A>:+5)TT^7$5:;O6J\R<YT84H1
M_"O$KQ$QO%N85\!@J]2AP[A*KAAZ$&X+'3I3:>,Q7++]YS-7H4Y6A2I\K4%5
M<YR<R@'"CKDX'J223ZG)R23DY)IHYZ<_3GU_P/Y&OM#]BW]@W]H?]N_X@7?@
M3X&>&H)K30EM;KQMXY\0W)TGP=X(TR]D:&WNM8OY$>XN[R[>*;[!HFBVFI:S
M?1P3W,-H+*WNKJ#^L?\ 9_\ ^#9_]D_P?H%E)^T5X\\?_&OQ@Q>74H_#.I3?
M#'P.CR.)/LUGINCM=>*)XX?FA^UW7BB-IT E%G;.VQ/H.+_%+@[@JM]4S;'U
M*V8J,)2RS+J*Q.,IQFDU*M'GI4<,G%J488BK3G43YHIQ3D>)POX=<4\645B<
MLP4*>!O*$<PQ]5X;"U'"R:I2Y*M:ND[QYJ%&K",HN$IQDFE_#0>.O'..?7T^
MM-(5O0X]_P#"O]"/Q%_P;P?\$S=:TV2STOX>?$?PA?;2MOK6@_%[QM>ZA:@J
M1^Z@\67_ (ETEQSTN-,GR. 1G(_![]N__@W=^-_P"T/Q/\4OV9O%<WQZ^'>B
MQ7NLW_@74+.VT;XI^&M"LH9;F[FM$CO3H_CU;*WA::8:-::1KDP(AL- OW!S
MX'#_ (Y\ Y_BZ>!>+QN48FM)4Z*SC#4\/AZLY2C&$%BZ.(Q%"G*3>GMY4HWL
MN8]K._![C3)L+/%O#8/,Z%-2E565XBI7K4X1BYRG+#UZ&&JS2MM1C5E?[)_.
M19W-Q97=K>V=Q/:WEI-#-:7=O<7$%S:S0.)(9;::"5);>6)P&BEA9)$<!@P(
MS7]7W_!'?_@N1XCT_7O#O[,'[:GC2YU[2]>N-+T/X7_'#Q ZS:AHNIW=R+*T
M\+?$K6I;A3?:1?W,]O9Z%XPNT>ZTVZ=+3Q)?7=E*-3TW^3MD>.1XV1U>)BLB
M.I1XRIY#H^&1@0048!U(*NJL" X2%6#H65ES@@E6!VLH975@RLNXD'YEZ@H<
MY'V_&/!>2<;Y34RS-Z,')Q<L%CZ:B\7@*_)^ZK8>K:3Y+M>UHR4J5:"Y)Q=E
M;Y+A?BS-^$<QI8[*ZTXP4K8K!RE+ZMBZ7-#GI5Z5TFVDU"HN6I2E[T9*S3_U
MWXI4FC21'5U=%=61@RLK $,I'!4CE6'##!'!J2OY\O\ @@+^W_J/[4GP%OO@
M/\4/$%WK/QI_9]LM/M(M3U27SM0\8?"FYS8>%M;GNG027VI^'9XF\,ZY<2RS
M7<P31M0O9I;C4Y';^@VO\Y^)>'\?PMGF8Y#F4.7%9?7]DYI?NZ]*48U,/B:5
M]72Q%&<*L+I-*5FDTS^[,@SK!\19/@,YP,KX?'4(U5%M.=*HKQJT*EFU[2C5
MC.G/O*+:T:(9Y5AC:0L %SD\=!D-UX^7KC(Y&.?NG^.;_@L1_P %Q=?O]>\0
M_LS_ +%/C*;1M%TJ74O#_P 4OCEX?\H:AJ^H)BRO?#?PPUF.>=K72[(F[MM9
M\5VEO;ZC=ZC L'AN^M[.SN+_ %#]%O\ @OA_P4)U']EGX#:9\#/A3X@N-(^-
MGQZM+VV;5M+E>#5?!/PQM)EM/$NNP7: R:=JWB*=V\.:%=(PNH%76KVU,-U9
M17,/\$3YW$G W$M@;B 6))&YV9VRQ)W.Q8YZX  _H/P+\+,)FM./&?$>%AB<
M'"LXY'E]>"E0Q%2A-QJYAB*<X2A6I4JL94L-"5X.M3J591ER0/Q'QA\1L5EE
M27"N15W0Q4Z*EFV-I-JM0A6BI4\%0FFG2K3IOGKS5Y1IU(TTU*4^6U>3W.H7
M-S>W]S/?7MY<3W=Y>7DAN;J[N[J5I[J[N;B;?+-=7,SO)/<R,TTCN[,Y+$U5
M*X.%7T' ZG ))[EV.6=CDLQ+'))-.B5F8*JEBQ50 ,\LRJ,GH.N?4X. :_HV
M_81_X-XOCC^T!I'AWXG?M->)Y?@'\.=92PU6P\#VVE6>L?%;Q%H=SY4Z&Z6:
M\_LKP*E[ QDA.L6VN:I&DH2[\.VHD+-_3G$O%O#W!V!AC,]S&C@*$FZ>&HI.
MIB,34A%-TL+A:2=2I)1Y4W&*A34H^TG%--_SQD'#6>\48Z6$R?!5L=55G6JW
MY,/AU-Q7M,3B)_NZ2=M.>7//E?LXSDN5_P XO49'(SC/;/IGUH'()'('4CH/
MKZ=1UK_0>\-?\&[W_!,[0]-BLM5^'OQ'\77J)MDUO7?B[XTM+^=N1O-MX6O?
M#>CP<8XM],CQPN2%!/SY^T'_ ,&T/[)'C/P_?2_L^>.OB'\%/&**)-,7Q%JD
MOQ1\%O(J.IMKW3=<GLO%""Y)CB-Y!XL=K5 S1V5P28V_+L-](CP_Q&)C0JK/
M<)3G/E^MXC+Z3H05TE.<</C,1B%#S5&4DK.48V9^CU_ WC>CAY5H/)\3.,>;
MZM0QU55Y.UW&#KX2A0<EKO7BG;W6V['\-"#AL$C< & .-R@AE![XSR,8SZXK
MZE_90_;,_:"_8K^(MG\0/@/XYU#P_++<P/XE\)7<]U>>"/'5E$R[](\6^'!,
MEIJ=O<HGDI<PBVU>R#N^CZA87;+,.G_;7_8+_:$_8*\?VO@GXZ^'K:&PUT7T
M_@GQ[H%P-1\&>.=-TZ>&"XNM$O1LGL[FS6XMS?Z%J]O8ZQ8":)Y8)[:XM+NY
M^-&X)C_B4[3Z94X//7'''%?KU.ID?%F3J</J.=Y)F="WO<E?"8FE))6E&2TG
M!IIQ?+4I5(M>[4INWY?*.<<-9NU)8S*<VR^LN97E0Q.&J1=E)-/6,XW::YJ=
M6E)-.=.:;_TW?^">/_!0CX3_ /!0/X-0>/O C_V'XW\.)8:7\4_AQ?/%_:W@
MSQ)/;.2\(CFN&U#PKK,MM>3^%]=&T:A:V\T-S%;:A9WUI!^@U?Y>W_!/O]L[
MQM^PI^TIX)^,OAR[U2X\*/?0:'\5?"&GW!6#QM\/[V5(=6TN:V96BEU/34F;
M7O#MP5$UMK&F6X1_*FN(;C_3<\!^.?#'Q+\&^%_'_@O4X=;\)>,_#^D>*/#>
ML6V?L^I:)KEC!J.F7L08!T%Q:7$4ACD59(R2DBJZLH_@_P 7/#I\!9[!X'VE
M3(,VC.ME=2<G4GAYTU#ZS@*T[:RH3FI49S;E5H3@VY3A-K^R?##CJ/&>3SCB
MW"&=98Z=',(02A'$0G%NAC:4.9\L:RC*%6"LJ=>G-)1C*"?\M?\ P=/_ /).
M_P!C@]U\;_&%A]3X<\$KS_P'(_'/7%?QL5_9/_P=/_\ ).OV.O\ L=?C#_ZC
MW@FOXV*_J?P'_P"389%_V%9VOE_;&-_S/YU\9/\ DX&<_P#7K*__ %58(_2#
M_@D#_P I,OV.?^RM1_\ J+^(:_TR*_S-_P#@D#_RDR_8Y_[*U'_ZB_B&O],9
MW5%+,< =2<#]3@?YXYK\,^DO_P E?DG_ &3E'_U88\_8/ '_ ))G./\ L>S_
M /5?@1LLJQ(SL<!<$]^,@$XR#QG/'Y'I7\??_!;S_@LH=1?Q-^QW^R=XNFCM
MK>74?#OQW^*OA^8)'=;/.L-2^&O@K6;>\4^5YC26OC+78!#AU.AZ==-&NK,W
MJW_!;S_@L<OP]B\4?L=_LJ^*[NV^(SR2:-\:OBCH,YA_X0>RD16N_ OA'45A
M!/C&\BE2'Q!K%E<1OX9L@^G64W]MW,UQHW\9[2[W=W+N\C,[R.0TDCNQ=GD?
M"EW9F)9W+.[9=FR2*]OP5\(?K#PO&'%6$_V=.&(R/*J\;.NXM2IYCC*<U_!O
M:6#HR5YN*Q%1>S]FI^1XL^)_LE7X7X<Q/[Z2E2S?,:,K^R3O&> PM2+TK=,3
M6BVH1;HP?M.=P1R6&XD\DD D_*&.XJ!GH&!/S;CDG).U-L<<5Q<306UI#)<W
M-S-';V]M$CR2W$\TB1PP11QJ\CR2R.L:)&CNS,%168@4 9('/) X#,>>. H/
MZXST!+%5;^R'_@B5_P $9O\ A$(O#/[8/[67A&"?Q5<Q:=K_ ,#_ (4Z]$DJ
M^%(':._TWXC>,+'>\#^)+J,VUSX5\/7\4K>'(6;6+^%-<GMK?1OZ'XXXVRC@
M/)JN:9G+FK34J>79?"<5B<?BDDXTJ7\E.*M*M6DN2E!-^]-PA+\-X0X0S3C#
M-(Y=@(\M./+6QV.G%^PP6&<^652;5^:I*TE1H+WZLD[<L(SG#T3_ ((G_P#!
M&>U^"MIH7[6'[5?A*WF^,FHQ6NM_"7X<ZPOG'X4Z=<0.8/$/B?3)[<0K\0;Z
M&XBGL;.5KD^$8#$TH@\1F1=,_J!50JA1T P*% 4    #  Z #@ <   8P  !
MT' I:_SSXIXHS;C#.,1G6<5O:8BLW&C1AS+#X/#IWIX7#0;?)2IJV[<ZDKU*
MLIU)2D_[BX;X<ROA7*J&4Y515.A27-5JR477Q5=I*IB<3423J59M?X81M3IQ
MC3C&*_![_@XW_P"4:GB'_LL_PA_].]_7^?T_WV_WF_F:_P! 7_@XW_Y1J>(?
M^RS_  A_].]_7^?T_P!]O]YOYFO[%^CC_P F_P 5_P!E%F?_ *A94?RYXZ_\
MEK2_[$67?^I69'=_"G_DJGPQ_P"RC^ O_4JTRO\ 5N^*'@'PS\5/AQXW^&?C
M.Q74_"?Q \*:[X.\1Z<X!6]T7Q'I=UI.HV_*2 -):W4H1BI"OM;((!K_ "D?
MA3_R53X8_P#91_ 7_J5:97^M2 "H!Y! !_*O@?I-5)T\=P35I2=.K2H9U.G4
MB[2C4AB<ME"<7;249133M=-)]$?8?1_IPK8/BRE4C&=.K/*Z=2$US1G3G2S"
M,XRB[)QE%M-/1IV/\H3]H[X'>)OV;/CO\5?@3XNA,6N?##QIK'A>20)(L=_I
MUI.9-!UF R11/):Z_H4NG:W:RE!OM[^,Y8@D^*<$$$ @XR#TX((_4 U_4Q_P
M<R_LH_\ "'_%;X5?M;^&=,C32/BAI[_#KXD7%K'M,7C7PE;+=^#=4O$109I=
M;\,?;-->4EMMOX45)F"M"&_EGK^A^ N):?%W"&1YXI1=?$814<?&*MR9CA9/
M#XR#5VX\U6FZL(O54ZL.C3?X?QGP_/AGB7-LH<9*A0Q+J8.4]?:8/$)8C#-2
MLE)PIU8TYR7_ "\A--)JQ_9!_P &R/[4HUKP9\8/V1?$>HRF]\%ZE;_%GX:6
MT[J5?P]XDN3IOCS3K$,W[J/3/$(T;6F@5,2S>)-2N$(=9"?ZR*_S /\ @FS^
MU _[('[:/P.^--U?RV?A6Q\40>%OB$D/S)<> O&.?#WB3[9&$F>6#2[34#X@
MAA2$N;_2;*:-A+&F/]/:UNX+V"&YMI$FMYXHYX9HV#QRQ2HLD<D;J2KHZ.K*
MRD@@Y''-?Q_X_<,?V'QM/-*-/DP7$F'CF$&D^58ZERT,P@M$DY35+$R766(D
M[O5G]1>"O$']K\(PR^M/FQ60XB6!:;3E+!5$JV"G9:J,(RJX6-^F&\RS1117
MX<?KX$XYX_$XK^3/_@YN_:M&E^%_A%^QWX<U0)J7BBYB^,GQ)M[:8JQ\*Z1<
M:IHO@71KP*V6AU;Q)#K&M21,N!/X9TI^4F.?ZN=9U.QT72-3UC5+B*STW2K&
MZU*_NYR%AM;.QA>YN;F5B0%C@AB>5V) 54+$C%?Y=W[?W[2]U^U]^UQ\:OCL
M]W>3Z%XE\6WVG^ ;>[9C_9OP[\/.VB^#;-(GYMR^C6<%_=1".+-_>W<[1B25
MRW[IX \+//>,XYM6I<^"X;H_79.2O!X^NIT<!'9KFIR=3%1O:TL/%IJ7*S\<
M\:^(O['X5>64:CCC,^J_5(J+M)8*BX5<;/=:23I8=[IJNTTU='QW^&/;T]J]
M[_9?^ OB;]I_]H#X2_ 7PE!(^K_$SQGI/AQ[I"0NE:5).+OQ#KUP0&*V.A>'
MK?4M6N716D\FPG$:M($!\$. &8D*%&>>.,@'GV4EO4[<#+$ _P!7G_!LS^R:
MFM^+OBO^V+XHTB*6P\(Q7'PB^%]Q=JLA/B34H-+UKQSKMC V6CEL=!GT30[6
M^& Z:UK5I&?,BNE3^NO$'B:/!_".<YVY1CB:.%E1R^,K?O,PQ35#"JS:;4*E
M15II-24*<G=6/YEX(X?EQ/Q/E64VO0J8B-?&NUU' X9JMBKZ.W/3BZ,6TTJE
M6%]TG_7;\/O 'AOX5_#[PE\.?!VFV^C^%O OA?1_"OAW3+50D%GI&@Z;#ING
MPJ!\S>7;VR!F?+,[,Q+,S,?\I[XR?\E>^*GO\1_&Y_$^)M3)_6O]9FY_U$G^
MX_\ Z U?Y,WQD_Y*[\4_^RC>-_\ U)=3K^>/HRSG5S'C.K4DYU*E#*9SG)N4
MI2G6Q\Y2DVVVY2DVVVVV]6S]S^D!"-/+.%Z<(J$*>*Q\(1BDHQA##X2,8I*R
M222225DD>;U]*ZA^U?\ &>]_9G\*_LDVOB:?0_@IH/B_Q'XYU#PWHDMU8-XQ
M\2Z]=PR_:/%\T=PK:K9:3#96@T?2VC_LV*=I[^:*2^^R2Q?-52",MM /+$ #
MZD>_7G@<9.!QFOZPQ&!P>.EA7B\-1Q,L%BH8W"*M!5%1Q=.%2G2KTT](U81K
M5%">\'*ZU/YHH8O%815UA<35PWUJA+"8CV,Y0=?#5)TYSP\^1ISI5)TZ;G!W
MC+E2DFALB@[02S!4"KN=W*JHQC<S%L8'<G'084 !H^;[OS=!QSR>@X]>WK7[
ME?\ !/3_ ((8?M!?MJ>'-"^+/CO6[;X%? K6F6]T+Q'JNG-K7C;QMI:3M#-=
M^%/"L>HZ:=-TVY:WFAM/$'B&\L89XBFH6&E:[8-%O_I!\$_\&Z?_  3=\-Z7
M#:>)?"WQ2^(VHK$%FUGQ)\5?$>E33,5 <K8^!SX2TR.-B"5!M97 ;!D; -?F
M'$WC9P'PUC*N7U\;BLTQU"<J>)I9/0IXN&'JPDHSIUL35K8;#^UC)24Z=*K5
ME!Q<9\CLG^A\/^$W&7$&%IXZCA,-E^%K0A4H5\TKSP\L33E'FC4IT:5'$8A0
MDFG&=6G3C-23A*2NU_GZX.2,'(ZC'(XSR.W'/TI57=D$D?*1D<$9X...#SP>
MH/(YK^YK]HK_ (-I_P!DWQCX7OI/V;?%WCGX'^.8HBVEIX@UW4/B1X$NG5@Y
MM=3TW79#XEM5N0OD?VAI_B,FQ5O/CTV[=3%)_'U^UE^R;\:?V,/B_J_P9^.?
MAU-#\1V5NNJZ+J5E<Q7_ (?\7^&;FZNK;3?%'AG4(FS>:3?O9W$>)H;>]L+N
M&XT_4[:SO[::W7U^#/$[A'CFI4PV48NM3S"G3E5GEF848X?%NE%I2JTX\]6C
M7I1O><J-6I*FFI5(4TTSRN*_#WB;A"$*V:X6C/ U)1IQS#!57B,(JDE=4JCE
M3I5:,Y;1]M2IQF](2E)-+B?@?\?/B]^S5\1M'^*WP1\;ZWX$\<:%(K6VI:1<
M2"&_M/,66XT76=-+&SUO0[\J4OM(U"&XM;E9'.Q9=DB_Z'W_  2P_P""D?@G
M_@H7\%FU=DLO#7QK^'UKH^E?%[P)"3'!:ZE=68:W\6^&$FN+BYG\&>)+B.];
M2C<2?;=,N;:[T>_5GM(;[4/\U_[PX[@]:^Z_^";O[8&N_L1_M9?#7XP0:I?6
MW@>XU6T\)_%K1[65C;Z]\.-?OK6VUU;JTVM'<S:'^X\1Z8[(S0:AI4"H0)G#
M>/XM>&^"XVR'$XS"X>G2XDRO#SK9?B8)1GBX4(\\\NQ#2O4IUH1E'#<S_<XA
MPDI1IRJJ7K^&?'6*X2S?#86O7G/(<?6A1QN'G+]WAI591A''4.:25*5*34J\
M4U&K1Y^:+G&G*/\ I^[E]1^8HK&L;E=0L;._L;B*:RO;6WN[2:)@\<MK<PI-
M;R1MY9W))$Z,C9.5(.3FBO\ /EV3:<DFG9IW336Z:MHT]&C^VT[I-)M.S32N
MG>UFGU7O(V&_A_WA_6O\S/\ X*\\_P#!2K]L(?\ 55KC_P!,^DU_IF,?N^[@
M?H3_ $K_ #-?^"O _P"-EG[86<\?%BX ."=Q_LC2, >Y/'?FOZ,^C0G_ *Y9
MR^BX;K+YO,LNMIN]F?@_C]KPSE*_ZGL?_5=C3\XR".H(^M(612-[*HR =S!1
MR-V,DCDJ"?H">@KV[X)?LX_'C]I/Q;9>"/@;\*?&'Q(\07EPEL$\/Z7*^E6+
MR$ 2ZWX@NQ:Z#X=M$)Q)>Z_J.F6B'K-CFOV\\%_\$&H/A#X83XG_ /!1']K?
MX6_LO^"[>V6]N?!OA[4K#Q;XYU-(X3-<Z59ZQ=W]EI2:FO&RS\+:1X^N+B4/
M;VEL R32?U5GG&W#'#DXT<US6E#&U%>AEF%IU<?FF)E=)0I9?A(5L4W-M1C*
M5)4^;24HZM?SGDW"7$6?PE6RS+:M3"4_XV/Q$Z6#R^A%6<I5<;BITJ"48^\X
MQE*;2TBS^=M5#RI#$IEF=UB2*/+2M(_W(UC7+,[_ ,* %F[ U^IW[*__  1L
M_;K_ &K[+3/$GAOX:V?PQ^'>IJ9K;XB?&6]N_!>C36ZE]]U8:*FGZIXOU:W^
M3RX9;30%L[J1XS'>QVSO=Q?H6_\ P4L_X)9?L012:9^P%^Q;:_&#Q]80K:V7
MQU^.)O+8PZ@(PZZS8GQ;;>(_B!()9'+/I=C;_#J.1"T*RVD<:1'\J/VG?^"H
MW[<'[5LNJ0?$CXX>)=)\&ZA<7#0_#7P!/)X#\"V>FSREH=(GTOPR^F7/B"VM
MHRD/G>*KS6[FY2-#=/(P&/G(YWX@<2)1R'A^APEE]1^YG/%C6)S&=)\J4\)P
M_@ZD7"I;6/\ :&,I4W97IN\HQ]MY3P1D2C+.,]K<3XU13_LOAI^RP,:ED^7$
M9YB8N$Z=W9O X:I/1M36E_Z^O^"-W[$OP/\ V)O$?Q\\#>#?VHO#G[0WQIU'
M3O $OQ=T;P9:6D'AWX>65I/XH3P_9));7VJ227VH7D^K_:%U&^AOT2UBWZ39
MQ@O-^\]?QU?\&L;-)XF_;)=F9G;1/@Z2SD,S?\3#Q[]XA5R2268@ $GY550
M/[%:_B_Q7P6.R_CW/,)F.9U<YQM/ZA+$9C6H4<+/$5*N782J[8?#KV5&E24U
M2HTXN7+3A%.4GJ?UAX;XO"8W@[*,1@<OIY7A)K&QH8&E6JXB-"%+'8BDDZ]9
MNI5G/E]I5J24>:I*344K(_ __@Y!'_&MK6/?XU_"8'W'VO6.#7[*? (;O@7\
M%2>2?A+\._I_R*&B]!T'X"OQK_X.0?\ E&WJ_P#V6SX3>W_+WK'>OV3^ ?\
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MG ?Q'BKP]C_/K7^:@'8]=I.3R47/4]?EY^M?Z5__  67_P"48O[8'_9,X?\
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MKB\5LVJ91P-G5:C-PKXJ%'+J4DVFOKU:%"LTU9J2PTJ\HM-6DD[Z'\U(
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M'@M_"'PXOK[P[;S6**72.TU[5(=5\3+_ *III-7EF="=NW\ZAM(#,,XZXX.
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M-AX0KXFC3KUUAZ=:O3A5Q52,ZD:,*E2,:E><87G45.,I5)1C[TK-+5G]-O\
MP1&_X(U'5I?"G[97[5GA:TGT6>TL]?\ @;\)]>MS=&\9V-SIWQ+\::7+ +=;
M;RFMKOP?H-S).TS,FMZG;6XCTZ&X_L+CC6- BC:O.%&0%!Z*O3  X'0\9ZUY
M?\%OBAX&^-/PO\"?%/X9ZI9ZQX#\=^%=%\2^&+ZR01(=*U2QAN+:UEML V5W
M8JWV*^T^1(9M/O;>>QN(HYK9XU]4K_-7C?BW/.,<^Q>8YZYTJ]*I4PU#+O?C
M1RNE3FU]3I4IV<)0:_?SDE4JU5*<_LI?WSPEPUE'#&38? Y1&-2C4A3KU<:^
M657'U)PC+ZS4G&\9*5_W48MPIT^6$=F%%%%?('U!^#W_  <;_P#*-3Q#_P!E
MG^$/_IWOZ_S^G^^W^\W\S7^@+_P<;_\ *-3Q#_V6?X0_^G>_K_/Z?[[?[S?S
M-?W1]''_ )-_BO\ LHLS_P#4+*C^/O'7_DM:7_8BR[_U*S([OX4_\E4^&/\
MV4?P%_ZE6F5_K5+T'T'\J_R5?A3_ ,E4^&/_ &4?P%_ZE6F5_K5+T'T'\J_/
MOI._[WP;_P!@V>_^I&7'V?T>_P#=^*?^OV4_^D9@?!O_  4M_9;C_;#_ &-/
MC3\%K>RM+KQ1?>'#XH^'D]V@Q8_$#P;*GB'PRT5QL9K3^T[JSDT&\G3)_LW5
MKV%@T4LJ/_F)W=I=6-Q-:7D$EM=6\LD-U;S1R)-;W$4CPRP2!U4H\4L<L<D;
MJ)4DC97PRLH_UWB,@@]""/SK_.._X+=?LJ#]EK]O/XAQZ-IT=AX!^-<(^-?@
M:*SM_(T^RB\4WMU9^*]$@13Y<;Z9XQTO6KA;555K?3=3TS]W##+"K1]&WBGV
M.,S?A#$U+0QD'F^6)M66)H1A2Q]&*=KNKAU2KI)Z?5JK49.3+\?.'G5PV5\3
MT(7GAIO+,PDDV_J]5^TP525K)1I5_:T6W=N6)IK9'Y&KM^4\!AD C:K<GU.
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MGE>7X6KB.53G1I8&IC)0>'I.,G7QE:KCG3PM'EDJE=4DXM-QE\1_MG?M"O\
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M_P#!;7KF:9YYKF?X;?9M,T:XN9I9II9;N?PG+X<GNY)F$D]Q-/<;0LBYS_\
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MK8BDDMV[)'Y%XW5X4N!,52DXJ>*S#+J-)-I-SC7^L2Y5U:I4:C:6MKO9-/\
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MDVZ^$BG.K@[M?'AM:E+WO>H<\(KEH)'["4445_,1_0Q^#W_!QO\ \HU/$/\
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MY!1116AB?Z\K_P '^^/Y&O\ ,U_X*]?\I*_VP\=/^%KW/_IGTGI7^F6W\/\
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MX(6?\I0/V;O^OCQ]_P"JU\85_H[5_G$_\$+/^4H'[-W_ %\>/O\ U6OC"O\
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MJ?AQ_P B!X&_[$WPS_Z9;&NVKB?AQ_R('@;_ +$WPS_Z9;&NVK_*2M_%J_\
M7R?_ *4S_22C_"I?]>X?^DH*_FD_X.7_ -G>Y^('[+_PS^/VCV=Q=ZG\!_'5
MSIFO+;6_G-'X'^)D=AIEY?RNJ,\<&F>*-'\+"8EUCB@O;F=P%5G']+=>4?&_
MX1>#OCK\(OB3\'_'ED+WPE\2?!^O^$=?A#,DBV.MZ?-9O=VT@93!?6#R1WUA
M<QE7MKVW@N4(>,&OH>#N(*G"O%&29_!2E'+<=3JUX0^*IA*BE0QE.-[)RJ8:
MK5C%-I.35VMSP^*<DAQ'P_FN33<8O'82I3HSEJJ>(@XU<-4:[0Q%.G-OI;0_
MR;E^8D*0VW&<$$8/W2"#@JP^9&!*NA5U)5E)];^ OQ@\2_L^_&KX6_&WP?AO
M$GPM\<>'?&FFVSM(D&HG0]2@O;K1KQHGCE_L[6;..XTS41'(KFSNY]C!L$=K
M^UM^S5\0_P!D#X_?$+X#?$?3KFVU3P9K-W;Z'JDT>RS\6^#WN;@^%_&6DNH,
M4EAXBTM8;LI')(UE?"]TZX\NYLYHD^<%;D-@$\-@@$ Y# \^A /OC!X)K_2Z
MC7R_/,KA4I2I8W*\VP5U.+4J>)P6,HV;O%M<M6E4:<;N4+N$O>BS^ IPQV49
ME.E4C/"9AEF*LXN\:E#%86JFGJM'"I!26G9ZG^KA^S7\?_A]^TY\$?AY\<OA
MKJUOJGA;XA>'=.UV%(9XKFYT34;FT@;5_#&L"W>5+77O#6HM<:-K%DS>9;WM
MG,#N7$C^[U_FS?\ !-S_ (*M?&S_ ()X>(;[2M%LH/B)\$?$^IKJOC#X2ZOJ
M(TNW_M-X;6QD\2^$==:SOY/#GB$6=O!%>/+#=Z;K$%M;PW]C)<1P:A9?V5?
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M_P!0M+5FW3JI_P!0DV\+QF)X8VC9'C:-D5D,;Y#1E<%2A'!7&".HY-?S"?\
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MBJT\=EM1KW9X3$R]HH0=FKX:I*>&FKN2]FI/2<6_ZH_^#;3]M[2? GB[QO\
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M,!IGAVQTZWE8;4DG\V147>17S$4 8GK]X8;E2"""& QE2"01G!&0>":<3GG
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MD7PDNKQM.^#NG?%O1(-Y@USX4^+-%U\W(4DA?^$>U2;0?%B2,@R%CT&=%?\
M=M*?E9_[6X8\8^!>):%-_P!KT,FQS454R_.:E/ SC)I7]EB*DWA,1!MM1=/$
M.;L^>G!W2_DOB#PMXPR"O**RROFV%O)T\;E-*IBX2BG9>TH4U+$T)-6;52ER
MZVC.>Y^.:, ""< XX[<9QQ[9X]*1G9B268Y[DD\?C[5]3>(OV&?VSO"MX^GZ
M[^RS\>-.O(Y3$\4WPO\ &,Z;P0"HN+#1KRV89/R,DSASZ  GTOP#_P $O_\
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MHI\?_$V9=K7-UX^\:"/5]4@N959EE_L"SDL/"\+QD1FVT:W*@Y9C^B]?YO\
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M)[RZFB+?%S0%<QR3R.I*&'()!R%(W#@'G-4_^(=[_@IG_P!"+\+/_#M:!_\
M(]?Z3TO$?@!4J:?&7#<6J<+J6;X)-/E5TTZUTUU32::::OH?P;6X!XUG7K2C
MPOG;3JU&G]0KI-2DVFKQ5TTUJ?AQ17[C_P#$.]_P4S_Z$7X6?^':T#_Y'HK3
M_B(_ '_19\,_^'C!?_+OZL_*^7^H'&W_ $2V=_\ A#6\O[OG^#['^@^W\/\
MO#^M?YF?_!7K_E)5^V%_V5:X_P#3/I-?Z9C?P_[P_K7^9G_P5Z_Y25?MA?\
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M@?\ (9O*_>\R1CK(@[<NO7CCK[C\Q7\F>.7_ "<K//\ KQE'_JHP1_9OT?\
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MG_@A9_RE _9N_P"OCQ]_ZK7QA7^CM7\0?20_Y+G+_P#LG,%_ZG9D?UWX#?\
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M:LU[B=U=;/5'F>N_Y!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M28R3JQU%-.E!TO1(?W:7#8^UM&T9.\5\&?\ #M;]L'.1\-M-S@#GQOX/'"C
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MM9S(R[PT-Q+*D<JE/G#1LPVY)(Q@^*>(_$[^-_V8-=\6SP+!/X@^%FIZG<0
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MI&93&HDVL",KP?D[QNH/[=WA\8^]J7A?IG)QX/@+ $$$<8) (SZ'%=A^T?\
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M5Y2E)I))+5MMI)+5O1)LX&U%.4FHQBFY2D[1BDKMMO1)+5M[(_E3_P"#FO\
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M_>$/VT_A3K\<2:^-4\'WKY$L5]9W.IV,;!02/[1TN"8A<_+NDLXNQQSQ^1Y
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MBBBJ$%%%% !1110 4444 %%%% 'A7[3/_)"?B3_V &_]*[6O)/V(?^217O\
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M]C?>?^FS2JV="Y_8Q.,'/PAU/_TWW77/0Y!'/>L;]A3_ ));KG4?\5?>=?\
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M4ZCKIQA/EORR<$I)/=--*S3/BKQI_P GX>'?]G4O#'_CW@Z '\@*^P/VE?\
MDAGQ'_[ +?\ I7;5\*'QGHGCS]M3PUXB\.7)OM)E\1Z7I]O>J/W5TVE^&WLY
MKBW+!2UM(\<BQN1\X02QED*L?O\ ^/>C7^O_  =^(FDZ7#)<ZC=^&+\VMO&
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MK]FLB, >0ZLRG/8G&#@CV'6?V'/A'J=_->V-_P"*M$@N7#R:=97VG7%I&H&
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M\K?HG]I5_P"6C_X _P#Y+^KORL?V7K?_ $"-3_\  "Z_^,4?V7K?_0(U/_P
MNO\ XQ111_96&_GK_P#@Q?\ R']7?E8_M*O_ "T?_ '_ /)?U=^5C^R];_Z!
M&I_^ %U_\8H_LO6_^@1J?_@!=?\ QBBBC^RL-_/7_P#!B_\ D/ZN_*Q_:5?^
M6C_X _\ Y+^KORL?V7K?_0(U/_P NO\ XQ1_9>M_] C4_P#P NO_ (Q111_9
M6&_GK_\ @Q?_ "']7?E8_M*O_+1_\ ?_ ,E_5WY6/[+UO_H$:G_X 77_ ,8H
M_LO6_P#H$:G_ . %U_\ &***/[*PW\]?_P &+_Y#^KORL?VE7_EH_P#@#_\
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M_P  +K_XQ1_9>M_] C4__ "Z_P#C%%%']E8;^>O_ .#%_P#(?U=^5C^TJ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
